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GENERAL AIMS
To study the effect of albumin contaminated with 
aluminium on the development of bone disease in 
patients with impaired renal function and to evaluate 
the interaction of citrate with aluminium and other 
metal ions in albumin solutions.
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SUMMARY
Human albumin, and other widely used blood products which 
are administered by injection, were analysed to determine 
the extent of aluminium and other trace metal 
contamination. Increases in metal ion concentrations from 
ten fold to several thousand fold the normal reference 
values were detected.
Detailed metabolic balance studies were undertaken on 
eight patients who were receiving repeated plasma exchange 
as treatment for a variety of illnesses using commercial 
albumin solutions known to be contaminated by trace 
metals. The quantitative retention and excretion of 
aluminium were measured in these patients and related to 
the degree of renal impairment. The excretion of this 
metal was proportional to creatinine clearance, with 
significant retention of an aluminium load in patients 
with poor renal function. The incidence of aluminium 
related bone disease was assessed from the clinical 
history, bone biopsy histomorphometry and administration 
of desferrioxamine as a mobilization test. Three of the 
four patients with poor renal function had bone disease.
The citrate anion which is used as an anticoagulant during 
the collection of whole blood donations was found to be 
present at high concentration in the final albumin 
product. Metal citrate complexes are formed during the
16
blood fractionation procedure, particularly during the 
depth filtration stage. These low molecular weight metal 
species are now being removed by the manufacturer after 
introduction of an additional ultrafiltration step which 
produces a ’clean’ product. The efficient renal excretion 
of aluminium and other metal citrate complexes has limited 
clinical toxicity following the injection of these 
contaminated substances, provided the patients have 
reasonably good renal function. A balance study on one 
patient who was treated with the newly produced clean 
product has confirmed this view.
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CHAPTER 1 INTRODUCTION
1.1 GENERAL INTRODUCTION
Aluminium has been shown to be the toxic agent in the 
pathogenesis of dialysis encephalopathy, Vitamin D 
resistant osteomalacia and a hypochromic microcytic 
anaemia in patients with renal impairment (1). In
addition there is epidemiological and scientific evidence 
linking aluminium as a possible toxin in Alzheimer’s 
disease, (2)(3) although its role as a primary cause in 
this widespread disorder is much disputed (4)(5)(6)(7).
Aluminium is the most abundant metal and the third most 
common element in the environment. Nevertheless, toxicity 
from this ubiquitous metal is relatively uncommon. An 
explanation lies in the very effective barriers which 
have been developed by man during the process of evolution 
to exclude this metal from the internal environment. The 
gastrointestinal tract, lungs and skin provide an almost 
impenetrable barrier to aluminium and if any of the metal 
does pass this barrier then it is dealt with by a most 
efficient renal excretion system.
Over the last fifty years industrial and domestic use of 
aluminium has increased considerably and these barrier 
mechanisms have been severely tested. In more recent 
years man has found even better ways of by-passing these 
natural defence mechanisms and has introduced aluminium
into the human body by the addition of aluminium
20
salts to pharmaceuticals.
The most clinically important source is aluminium- 
contaminated water used in the preparation of renal 
dialysate. Large amounts of oral aluminium hydroxide are 
also administered as antacids and used as phosphate- 
binders in patients with impaired renal function. It took
some time before the medical and scientific world
recognised these potential sources of aluminium toxicity
and took effective action to minimise poisoning in the ’at
risk’ population.
Another important source of aluminium intoxication has 
received little attention. Albumin solutions are widely 
used as plasma expanders and it is estimated that over ten 
million grammes of this protein solution is infused into 
patients in one year.
Albumin was first shown to be contaminated with aluminium 
in 1978 (8) and since then manufacturers have claimed that 
the aluminium concentrations present in these solutions 
are too low to pose a threat. They have argued that the 
volumes administered are so small that the risk is 
negligible compared to environmental sources of aluminium 
and aluminium-containing drugs such as phosphate-binders. 
The manufacturers of albumin solutions have put the onus 
on clinicians to show evidence of aluminium toxicity in 
patients receiving these solutions. It is true that many
patients receive small volumes of albumin and therefore 
the risk of toxicity may be low but there are many
patients, and particularly those with impaired renal 
function, who may receive large quantities of albumin over 
many years. One such group comprises patients receiving 
chronic intermittent plasma exchange.
Albumin solutions and other blood products marketed by all 
the major manufacturers in the United Kingdom were studied 
for evidence of contamination with aluminium and other
trace metals. . Detailed metabolic balance studies and bone
biopsies were performed on patients receiving albumin 
solutions to determine whether or not they developed
aluminium bone disease.
The results of these investigations were made available to 
the manufacturers of the products examined. One of these 
manufacturers, the Protein Fractionation Centre, Scottish 
National Blood Transfusion Service responded to the report 
and collaborative studies were set up to determine the
sources of metal contamination. The possible role of
citrate-metal complex formation in enhancing renal
excretion of these metals was evaluated.
22
1.2 HISTORICAL BACKGROUND
Aluminium derives its name from alum which was used 
medicinally as an astringent in ancient Greece and Rome 
(Latin alumen: bitterness). The impure metal was first 
isolated by the Danish scientist M C Oersted in 1827 and 
it became commercially available in 1854. So precious was 
the metal at this time that it was exhibited next to the 
crown jewels at the Paris Exposition of 1855 and the 
Emperor Louis Napoleon III used aluminium cutlery on State 
occasions.
Charles Dickens predicted that this newly available metal 
would soon displace iron and copper in kitchen utensils 
and that respectable babies would be born with aluminium 
spoons in their mouths. A dramatic thousand fold drop in 
the price of aluminium occurred before the end of the 
century. This was due to the advent of cheap electricity 
and advances in the purification techniques for aluminium. 
World production rose quickly and aluminium became 
available on a massive scale.
Aluminium is the most abundant metal in the earth’s crust 
(8.3% by weight) and industrial use of this metal exceeds 
ten million tons per year. Daily exposure to aluminium, 
either from environmental or industrial sources, is 
virtually unavoidable. Whether such exposure to aluminium 
is a threat, or is innocuous, or is even necessary and
23
beneficial to human health are questions which have as yet 
not been completely resolved.
Throughout the century since the metal has appeared in
commercial quantities and as its use in food packaging,
cooking utensils, beverage cans and piping has expanded 
there has been concern about its possible toxicity.
In 1913 the corrosion of cooking pots as a potential 
source of aluminium was debated in several leading 
articles in the Lancet(9)(10). Their conclusions were
reassuring as were those of many other investigators in
the first half of this century.
One of the first reports of poisoning which was attributed 
to aluminium was in 1921 (11). The patient, a metal
worker, had loss of memory, tremor, jerking movements and 
incoordination. Five years later attention was drawn to 
the potential health hazards of the aluminium present in 
city drinking water and various medicines(12). This 
warning was largely ignored and in the 19^0’s inhalation 
of aluminium powder became popular as a method of treating 
silicosis. Patients were exposed to regular inhalations 
of fine particles of aluminium for periods of many years 
without any reported adverse tissue reactions. The
procedure was apparently abandoned because of doubts about 
its efficacy and its unpleasant nature rather than for 
fears of toxicity. It is said that 30,000 workers
2k
survived the treatment.
In 1957, a team of environmentalists from Cincinnati
studied over 1500 books, articles and other manuscripts 
and wrote an exhaustive review of the 500 most
informative(13)• In 1974, another team from the same 
department extended the review -to a further 800 papers 
published in the intervening 17 years(l4). At the end of 
each review they concluded that there was little need for 
public alarm and that no major health hazard had emerged
despite very extensive use of aluminium.
They did however acknowledge the deficiencies of many of 
the methods used to measure aluminium in the studies they
reviewed and much of the quantitative information they
quote in their tables has had to be interpreted with great 
caution.
Nevertheless, they discussed three possible adverse 
effects of aluminium. These included neurologic damage in
experimental animals and a possible relationship to
Alzheimer’s disease, aluminium retention in chronic renal 
failure, and bone disease as a result of phosphate 
depletion caused by aluminium hydroxide administration.
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1 .2 . i CONCERN ABOUT ALUMINIUM OVERLOAD IN RENAL
FAILURE
In the 1950’s and 1960’s, aluminium hydroxide was used 
world wide as a phosphate-binder in chronic renal failure. 
However, the debate about aluminium toxicity was started 
by the introduction of a new trial drug, an aluminium- 
phase resin for the control' of hyperkalaemia(15).
Berlyne et al.(l6) were the first to draw attention to 
aluminium-containing pharmaceuticals when they reported 
the finding of hyperaluminaemia in renal failure patients. 
The values were increased in some patients on oral 
treatment with aluminium-phase resins and aluminium 
hydroxide, and in some patients on dialysis treatment who 
were not taking oral aluminium salts, but who had been 
exposed to a dialysate with a relatively high aluminium 
content. Berlyne and co-workers proposed that the 
increased values in these patients were probably accounted 
for by considerable absorption of aluminium ions from the 
intestine and impairment of the normal efficient renal 
mechanism of excretion of aluminium.
Berlyne’s team measured serum aluminium by neutron 
activation, colorimetric tests, and atomic absorption 
spectroscopy. However, their results were so far from 
those obtained today that they cannot be interpreted as 
confirming Berlyne’s contention (though it eventually 
proved correct in all respects). The normal range of
26
aluminium concentration in serum was 20 - 100 times higher 
than the current figures and values for patients as high 
as 2000 and 4000 umol/1 were reported (typical figures for 
patients consuming aluminium-containing medications today 
are in the range 1 - 15 umol/1).
They subsequently reported the effects of ' aluminium 
poisoning in uraemic and non-uraemic rats after modest 
doses of oral and parenteral aluminium salt(17).
Intra-peritoneal aluminium hydroxide was rapidly lethal to 
uraemic rats but not to controls. Oral aluminium sulphate 
and chloride were equally lethal to uraemic rats but not 
to controls. The intoxicated rats developed periorbital 
bleeding, corneal atrophy and heavy aluminium overload in 
liver, heart, striated muscle, brain and bone tissues.
It is understandable that Berlyne and his co-workers were 
alarmed by the lethality of aluminium in renal failure, 
but in view of the unusual routes of administration their 
recommendation "that pending further work, aluminium salts 
should not be prescribed for patients with renal 
functional impairment, and that they should be withdrawn 
from the market” was regarded as over-zealous. A lively 
controversy arose for a while although reports by Clarkson 
et al.(l8) encouraged caution in the use of aluminium 
hydroxide.
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After 1972, the debate on aluminium toxicity in the renal 
literature subsided and little was heard of the subject 
for the next four years. This was partly due to the lack 
of reliable methods of measuring aluminium in biological 
samples suitable for the detection of the very low 
concentrations of aluminium found in blood and tissues of 
normal subjects.
It was during these years that the first reliable methods 
were developed independently by Le Gendre and Alfrey,(19) 
and Fuchs et al(20). They described flameless atomic 
absorption spectrometric methods and were probably the 
first authors to show by reasonably accurate methods that 
phosphate-binders cause an elevation of serum aluminium.
It was also during these years that the two main clinical 
syndromes were described with Alfrey's account of 
encephalopathy (21) and Schorr's description of bone 
disease(22).
28
1.2.ii RECOGNITION OF ALUMINIUM INDUCED DISEASE
Dialysis encephalopathy
In 1972, Alfrey and his colleagues gave the first account 
of an outbreak of encephalopathy in a dialysis unit. They 
suggested that this was an intoxication and that the 
source of the toxin was the water used to make dialysis 
fluid(21). The first manifestation in these patients was 
a speech disorder, followed by dementia, convulsions and 
myoclonus. The syndrome was recognised in many other 
dialysis centres and considered to be a metabolic disorder 
of unknown aetiology.
By 1976 a sufficient number of papers describing this 
disease had been published for nephologists to accept it 
as a distinct entity(23). Alfrey and his colleagues 
subsequently proposed that this syndrome (dialysis 
encephalopathy or dialysis dementia), which developed 
after three to seven years of treatment, could be due to 
aluminium intoxication(24). Their proposal was based on 
the findings of increased aluminium content in brain, 
muscle and bone tissues in affected patients.
They proposed that increased tissue aluminium content in 
patients with the dialysis encephalopathy syndrome was 
derived from the oral aluminium hydroxide which had been 
administered therapeutically to control their serum
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phosphate. In support of this proposal was the evidence 
of a positive aluminium balance in patients with chronic 
renal failure on haemodialysis treatment who were taking 
oral aluminium containing phosphate binding gels(l8).
In spite of their earlier contention that the source of 
the toxin in dialysis encephalopathy was the dialysis 
fluid, when the evidence pointed to aluminium they were 
beguiled by the fact that their patients had been 
enthusiastically treated with aluminium hydroxide.
However, Alfrey’s failure to mention the dialysate 
remained a puzzle and it seemed to have affected many 
other nephrologists with the same temporary blindness to 
the obvious.
The event which redirected attention to the dialysate was 
an outbreak of encephalopathy in one dialysis centre where 
the dialysis fluid was specifically shown to be the source 
of aluminium toxicity(25).
Following this, a survey (26) of water supplies throughout 
Great Britain showed an association between high tap water 
aluminium and the occurrence of encephalopathy so highly 
significant as to suggest that water aluminium was 
virtually the only important influence. Of course an 
association between water aluminium and encephalopathy 
does not constitute proof of causation.
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Most of the existing evidence is now consistent with the 
notion that the excess brain tissue aluminium of dialysis 
encephalopathy syndrome stems from the dialysate with some 
contribution from the gastrointestinal tract.
That aluminium is the major toxic factor in the dialysis 
encephalopathy is now widely accepted (27)(28)(29) • in an' 
epidemiological analysis of six dialysis centres, using a 
uniform clinical classification, 55 patients with dialysis 
encephalopathy were identified (30). Dialysis
encephalopathy was the direct cause of death in most 
cases, and the disease appeared to shorten survival 
significantly. The overall attack rate of dialysis
encephalopathy was 4% and varied among the six centres 
from 2.2 to 14.7%.
The difference in the rates was explained by variations in 
aluminium exposure in the dialysate water. The risk of 
developing encephalopathy was significantly related to 
cumulative aluminium exposure in the dialysis water. It 
was also accepted that this syndrome had a common 
aetiology with one of the osteomalacic components of 
dialysis osteodystrophy (31) (32
Hyperaluminaemia and dialysis encephalopathy may occur not 
only in patients on haemodialysis treatment but also in 
those on peritoneal dialysis,(33) and in some patients who 
have not been dialysed (34)(35). The non-dialysed
patients are usually children with renal failure who have 
been on oral treatment with aluminium hydroxide. Other 
workers have proposed that the aetiology of dialysis 
encephalopathy syndrome is multifactorial (36)(37). Even 
if this is so, aluminium undoubtedly has a major role.
Dialysis osteodystrophy
Whereas encephalopathy is a clear-cut syndrome most likely 
due to a single cause, aluminium bone disease merges into 
osteodystrophy of renal failure and the inter-relationship 
grows more complex as the literature expands. Bone pain, 
as a consequence of metabolic bone disease, is a common 
symptom in chronic renal failure patients on long-term 
intermittent haemodialysis. The progressive metabolic 
bone disease in these patients should be called ’dialysis 
osteodystrophy’ a term that distinguishes it, and some 
aspects of its pathogenesis, from renal osteodystrophy in 
the undialysed patient.
The osteomalacic component of dialysis osteodystrophy is 
particularly troublesome in being associated with a high 
incidence of fractures. The reported incidence and rate 
of progression of the various components of dialysis 
osteodystrophy has varied not only between countries but 
also between dialysis centres within a country, despite 
apparently similar dialysis techniques (38)(39). The 
characteristic of dialysis osteodystrophy is that it
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progresses or develops despite the maintenance of plasma 
calcium and magnesium, at concentrations which in a 
healthy person would not interfere with bone 
mineralization (40). In the bone mineralization process 
the availability of phosphate, for the formation of 
hydroxyapatite crystals, is of crucial importance. 
Phosphate deficiency, with hypophosphataemia, is a 
recognised cause of osteomalacia. The administration of 
aluminium-containing medications can induce a state of 
phosphate deficiency.
Attention was drawn to the direct role of aluminium in 
renal osteodystropy in 1971 when Parsons and co-workers 
reported an increased bone content of the element in 
patients with end-stage chronic renal failure (41). The 
aluminium content tended to be highest in patients who had 
been longest on haemodialysis. There was no correlation 
between the bone aluminium content and the amount of oral 
aluminium hydroxide that the patient had consumed. 
Although Parsons and his colleagues (41) did not at that 
time speculate on the potential sources of the aluminium, 
their observations could have been interpreted as pointing 
to the haemodialysis procedure itself.
In 1977 Platts et al. reported (42) on the prevalence of 
dialysis encephalopathy and spontaneous fractures in 202 
patients on home dialysis for chronic renal failure. 
Noting the uneven geographical distribution of these
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complications they investigated the water supplies. In 
the tap water of patients with fractures or 
encephalopathy, the concentrations of aluminium and 
manganese were higher than those in the water of patients 
without the complications. The patients with multiple 
fractures had been dialysed against water with higher 
aluminium and manganese content than those patients with a 
single fracture. Platts et al.(42) did not incriminate 
aluminium hydroxide ingestion in the genesis of these 
complications because only some of the patients took the 
gel, and even then, not consistently. Instead, they 
concluded that some contaminant in the water used for 
dialysis was very probably responsible for the development 
of dialysis encephalopathy and pathological fractures. 
Although they did not definitely incriminate aluminium as 
the toxic contaminant, they proposed that in areas with a 
high aluminium content in the tap water the patients 
should be dialysed with deionized water. The beneficial 
effect of using deionized water to prepare the dialysate 
was subsequently confirmed by other workers. Ward and his 
colleagues reported (43) that after one to four years of 
haemodialysis, osteomalacia was evident in only 15% of a 
group of patients using deionized water compared with 70% 
of a group using softened non-deionized water from the 
same source. In their dialysis centres which used tap 
water with a high aluminium content both osteomalacia and 
dialysis encephalopathy were encountered. The close 
association between these complications, in their
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judgement, was consistent with a common aetiology. An 
epidemiological survey of 1,293 patients in 18 British 
dialysis centres showed a highly significant correlation 
between the aluminium content of water used to prepare the 
dialysate and the incidence of osteomalacic dialysis 
osteodystrophy and dialysis encephalopathy (26). The bulk 
of the evidence (44) (45) (46) (*17) now supports the notion 
that aluminium is at least a very important aetiological 
factor in one type of osteomalacic dialysis 
osteodystrophy. The particular type of osteomalacia 
induced by aluminium is progressive, associated with a 
myopathy , and relatively resistant to treatment with 
either Vitamin D or its biologically active metabolites. 
In some series it has been associated with a high 
incidence of hypercalcaemia (48). The usual source of 
aluminium seems to be the tap water from which the 
dialysate is made. In addition there is undoubtedly some 
intestinal absorption from the phosphate-binding gels, and 
in some patients this seems to have been the dominant 
factor (35)(49). It is possible that individual aluminium 
absorption rates vary and that some patients may absorb 
excessive amounts from the intestinal tract after oral 
administration. The driving force for aluminium transfer 
during haemodialysis seems to be the effective 
concentration gradient between the dialysate aluminium and 
the free diffusible plasma aluminium (50).
The mechanism for the disordered bone formation induced by
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an excess of aluminium remains to be determined. 
Aluminium was one of the polyvalent metal ions whose 
effect on the stability of a calcification buffer was 
studied by Bachra and Van Hanskamp (51). They reported 
that at concentrations of 1 umol/1 (27 ug/1) or less 
aluminium ions destabilised the buffer, and they proposed 
that polyvalent ions such as-aluminium, by formation of an 
insoluble phosphate, could initiate the precipitation of 
calcium apatite. This effect of aluminium in vivo would 
presumably interfere with the normal orderly deposition of 
bone mineral. In laboratory animals a striking increase 
of bone aluminium content with a disturbance of the 
mineralization process and the development of osteomalacia 
has been reported after intraperitoneal injection of
aluminium chloride (52). The defect in mineralization did 
not arise immediately after the increase in bone 
aluminium, but after quite a long lag phase. 
Histologically the mineralization defect was characterised 
by an excess of osteoid. On the evidence of electron- 
probe X-ray microanalysis, and a specific histochemical 
stain, the aluminium in haemodialysis patients with 
osteomalacia, was mainly localised at the interface
between the osteoid and the calcified matrix (48)(53)(54 ). 
The interface, or calcification front between the 
mineralised and non-mineralised matrix is normally the 
first site of bone mineral deposition. Cournot-Witner et 
al.(53) found no such localisation in patients with
osteitis fibrosa and proposed that aluminium was
distributed diffusely throughout the bone tissue. These 
patients had higher plasma concentrations of 
immunoreactive parathyroid hormone, histologically 
increased osteoclast surface, and marrow fibrosis. 
Cournot Witmer et al.(53) concluded that osteomalacic 
dialysis osteodystrophy arises only in the absence of 
severe secondary hyperparathyroidism and proposed that the 
action of aluminium on bone cells and matrix 
mineralization may in some way be modulated by parathyroid 
hormone. The localisation of aluminium to the
calcification front is encouraged by a low level of 
parathyroid activity, at least as judged by the effect of 
parathyroidectomy (55).
A reasonable, though not certain, interpretation of 
current data is that aluminium accumulation suppresses 
parathyroid activity, encouraging aluminium deposition at 
the ossification front and producing a vicious spiral of 
disease.
Microcytic anaemia
This is often the first clinical manifestation of 
aluminium intoxication and also the most readily 
reversible, so it is surprising that it was the last of 
the major syndromes to be recognised. Nearly all patients 
with chronic renal failure have a normochromic normocytic 
anaemia. The aetiology of the anaemia has several
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components and it is not simply the end result of a 
decrease in renal production of erythropoietin (56). In 
1978 Elliott and MacDougall reported (57) that anaemia was 
associated with osteomalacic dialysis osteodystrophy and 
with dialysis encephalopathy. In the encephalopathy 
patients the haemoglobin fell before the onset of 
neurological symptoms and in the osteodystrophy patients
before bone complications. The mechanism by which an
excess of aluminium induces anaemia remains to be 
determined.
Aluminium is deposited in bone marrow cells, particularly 
the reticular cells of the erythroblastic islets (58) 
where it presumably interferes with the accumulation of 
haemoglobin in developing red cells.
The anaemia caused by aluminium poisoning is non-iron
deficient, microcytic and hypochromic, and responds to use 
of a low-aluminium dialysate (59)(60). In view of the 
nature of the anaemia induced by aluminium toxicity, 
O ’Hare and Murnahagan (60) have proposed that it may be 
due to a disturbance in haem synthesis, specifically 
involving cf-amino-laevulinic acid (ALA) dehydrogenase. 
Another possible explanation is that aluminium interferes 
with the transport of iron by competing for its binding 
sites on transferrin.
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1.2.iii ALUMINIUM ACCUMULATION IN INDIVIDUALS WITH
NORMAL RENAL FUNCTION
Further evidence of the harmful effects of aluminium comes 
from studies of aluminium accumulation in subjects who 
have normal renal function.
Oral aluminium
The widespread distribution of aluminium compounds in 
nature and their prevalence in water, foods such as infant 
formula feeds (61) and tea (62) as well as release from 
cooking utensils have stimulated considerable interest in 
the absorption of aluminium from the gastrointestinal 
tract. It has been estimated that the daily intake of 
aluminium in an average diet can vary from 2 to 160 mg 
(0.1 to 5.9 umol) (13) (1*0(63).
In the early 1900’s, a number of studies, both in man 
(64)(65)(66) and in experimental animals (66) (67)(68) were 
designed to investigate the absorption and excretion of 
aluminium. In the first systematic investigation (64) of 
this issue volunteers were fed biscuits or pancakes made 
from baking powder containing sodium aluminium sulphate. 
There was no significant increase in serum aluminium 
concentration detected and less than 0.1% of the ingested 
aluminium was excreted in the urine. Thus, it was 
concluded that aluminium is not readily absorbed through
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the intestine and only trace amounts appear in tissues.
A number of modern studies have provided substantial 
evidence demonstrating some absorption of aluminium from 
the gastrointestinal tract (16)(69)(70)(71). Collectively 
these investigations indicate that the gastrointestinal 
absorption of aluminium is dependent on the dose as well 
as the chemical and physical form of aluminium 
administered. However, the precise relationship of the 
dose ingested to the dose absorbed is yet to be defined, 
although the best available data on this issue comes from 
balance studies (18) (64)(72)(73).
The data from the five balance studies were combined and 
more closely examined to investigate the relationship 
between the amount of aluminium ingested and the actual 
amount absorbed (74). Aluminium balance studies were 
completed in normal healthy subjects with careful 
monitoring of the aluminium ingested in the diet and from 
a variety of antacids. All faeces and urine were
collected and analysed by atomic absorption spectroscopy. 
Absorption was defined as the difference between the dose 
administered and the concentration excreted in the faeces. 
A compilation of the data in 29 subjects is shown in 
Figure 1.1 which compares the dose of aluminium per day 
with the amount of aluminium absorbed per day. The levels 
of ingested aluminium cluster at three values, 
approximately 10 mg(0.3 mmol)/day,125 mg(4.6 mmol)/day,
and approximately 2000 mg(74 mmol)/day. There was no
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appreciable absorption at the two lower doses. However, 
absorption does occur at the high (therapeutic) dose 
levels.
The precise prediction of the amount of aluminium absorbed 
for a given dose is not possible from this data. However, 
the simple connection of the confidence intervals of the 
three dose ranges provides an indication of the limits 
that such a dose-response curve might follow (Fig 1.1). 
Using this, it is possible to speculate that in a balance 
study no measurable absorption would be expected until the 
daily dose exceeded 225 mg(8.3 mmol)/day. The current
evidence demonstrates that a dose-response relationship 
does exist for the gastrointestinal absorption of 
aluminium.
The absorbed aluminium that is not excreted could 
accumulate in tissues. Recker et al. (70) reported a 
patient who had chronic peptic ulcer disease and had been 
taking aluminium-containing antacids for 25 years. He had 
osteomalacia, and his bone aluminium was 24 ug/g. This 
was certainly higher than the normally accepted value of 
less than 8 ug/g,(75) but much lower than the levels seen 
in patients with renal failure.
There have been other reports of osteomalacia in normal 
individuals who ingest large quantities of aluminium- 
containing antacids.(76) It is not clear from these
studies whether the bone pathology was the result of 
aluminium accumulation or the effect of disturbance of 
mineral balance with hypophosphataemia and negative
calcium balance.
Although the available evidence would suggest that there 
is negligible absorption of aluminium from the normal diet 
there has been considerable public concern (77)(78)(79) 
about the undesirable effects of dietary aluminium in food 
sources, e.g. tea, infant feeds and from cooking pots.
However, there is little evidence to suggest that they are 
of more than marginal importance, contributing only a few 
milligramme per day to intake, compared with several
grammes per day from phosphate-binders (80). The use of 
aluminium pans increase the aluminium content only
slightly (81) (82). For example, it would take 20kg of 
cabbage soup boiled in an aluminium pan to equal one 
teaspoon of aluminium hydroxide. There are about 30mg 
(1.1 mmol) of aluminium in 80mg (3*0 mmol) of aluminium 
hydroxide (70) so a teaspoon of antacid will deliver about 
125 (4.6)to 150mg (5*6 mmol).
A recent report (78) suggested that tea which contained up 
to 100 mg/1 (3*7 mmol/l) of aluminium could be a very 
important source, but other studies (83)(84) show a 
maximum aluminium level of 4.9 mg/1 (0.2 mmol/l) which is 
insignificant in comparison with medicinal doses.
The one food source which may be of significance is 
formula feeds for infants. Aluminium concentrations
varying between 94 ug/1 (3.5 umol/1) and 1330 ug/1 (49-3 
umol/1) were found in some milk formulae (61) and it was 
estimated that a typical infant would receive 17 (0.6) to
240 ug/kg (8.9 umol/kg) daily. Although this daily oral 
intake might not be regarded as excessive in adults, it 
may be potentially toxic to infants with immature or 
impaired renal function.
High urinary aluminium levels have been found in full- 
term infants with normal renal function suggesting 
increased gastrointestinal absorption at this age. In the 
presence of altered renal function which is common in pre­
term infants, aluminium excretion may be reduced, and 
accumulation ensues.
Aluminium toxicity with increased brain aluminium has been 
reported in uraemic infants who were fed entirely with 
oral milk formulae contaminated with aluminium (85).
The tap water used for reconstituting feeds could also be 
contaminated with aluminium. In the North-West of England 
tap water aluminium concentrations range from 10 (0.4) to 
300 ug/1 (11 umol/1)(3). European Economic Community 
provisional regulations set the maximum aluminium 
concentration in drinking water at 200 ug/1 (7.4 umol/1).
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The potential toxicity of this source of oral aluminium to 
the general public has recently been highlighted in a 
survey of 88 county districts in England and Wales which 
have varying levels of aluminium in the water. The risk 
of Alzheimer’s disease was 1.5 times higher in districts 
where the mean concentration of aluminium in the water 
exceeded 4 umol/1 than in districts where concentrations 
were less than 0.4 umol/1. Subsequent correspondence 
disputes these findings and the role of aluminium in the 
aetiology of Alzheimer’s disease (4) (5)(6)(7).
The extent to which aluminium is absorbed from the 
intestinal tract depends not only on the dose but also on 
its chemical form and further research is required to 
assess the bioavailability of aluminium from tap-water 
compared with other sources in the diet and to determine 
the fate of the absorbed aluminium within the body.
Parenteral aluminium: 
intravenous nutrients
The parenteral route which bypasses the gastrointestinal 
barrier has proved a greater source of anxiety. Tissue 
accumulation of aluminium in patients with normal renal 
function due to the inadvertent adminstration of 
parenteral aluminium was first described in patients
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receiving long term total parenteral nutrition. A
syndrome of bone pain and fractures was found in patients
from Los Angeles and Seattle (86)(87). They had a variety 
of gastrointestinal diseases with malabsorption. They had 
not been taking large amounts of antacids. The bone
symptoms developed months to years after the 
administration of the total parenteral nutrition, at a
time when the general nutritional status had improved. 
These patients had normal serum levels of calcium,
phosphate, magnesium, bicarbonate, copper, zinc and
albumin. The serum alkaline phosphatase activity tended 
to be higher than normal, but the parathormone levels
were usually low, or in the lower part of the normal
range. Vitamin D levels were normal, but 1,25
Dihydroxycholecalciferol was decreased. The patients had 
normal renal function with a mean creatinine clearance of 
82 ml/min. The urine calcium was very high, especially
during the total parenteral nutrition infusion, with a
mean value of 456 mg (11.4 mmol) over 12 hours.
Bone biopsies from 14 out of 16 patients demonstrated poor 
bone formation as measured by double tetracycline
labelling. Some of the patients had increased osteoid
(osteomalacia) but others had normal or even decreased
osteoid (aplastic bone). There was no fibrosis and the
osteoblasts and osteoclasts did not appear active. Total 
bone area was also decreased. Aluminium stains were 
positive covering 4% to 77% of the bone surface. In the
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other two patients no aluminium stain was seen. The cells 
appeared more active, and one had slight amounts of 
fibrosis. The bone formation was normal. The bone 
formation rate in this group of patients was significantly 
correlated with the bone aluminium concentration (88).
The patients with aluminium in the bone had been receiving 
intravenous nutrition with amino acids in the form of 
casein hydrolysate, whereas the other two patients had 
received synthetic crystalline amino acids. Further
investigation of the total parenteral nutrition solutions 
revealed that the casein hydrolysate contained 2,313 + 149
ug/1 (85.7 +_ 5.5 umol/1) of aluminium. The crystalline
amino acids had only 26 ug/1 (1 umol/1) and there were 
only small amounts in other fluids such as dextrose. 
These patients had been injected with 2(0.07) to 3*5 mg 
(0.13 mmol) of aluminium per day. Their plasma aluminium 
was 154 ug/1 (5.7 umol/1) and bone aluminium ranged from 
50 to 250 ug/g. Liver aluminium was also elevated at 84 
ug/g (87) *
Klein et al.(89)(90) did a series of studies in small 
groups of these patients to evaluate the aluminium 
kinetics. The plasma concentrations were measured after 
10 hours of infusion. At rates of infusion of 2 ug (0.07 
umol) of aluminium per minute there was no increase in the 
plasma level, suggesting rapid tissue uptake of the 
aluminium. The plasma levels did rise if the infusion
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rate was 3 ug/min (0.11 umol/min). Urine aluminium
averaged 1264 ug/day (46.8 umol/day) compared to the 15 
ug/day (0.6 umol/day) seen in normal controls. The ultra- 
filterable aluminium was 5.5% of total serum aluminium, so 
that the calculated fractional excretion was 5% to 20%. 
The mean renal clearance of aluminium was 10.6 ml/min. 
The overall urine excretion was less than the load. In 
three patients balance studies were carried out. The 
faecal losses were small, only 5(0.2), 26(1.0) and 71
ug/day (2.6 umol/1). Thus, the net retention of aluminium 
was 438 (16.2) to 1,337 mg (49-5 umol) per infusion.
In both renal and total parenteral nutrition patients the 
parathormone and 1,25 Dihydroxycholecalciferol levels 
are low. These hormones may play a role in the 
pathophysiology of bone disease. It is possible that the 
aluminium itself may inhibit the parathyroid gland or the 
1-o -hydroxylase in the kidney.
To study this, calcium was eliminated from the total 
parenteral nutrition solution until the patients serum 
calcium fell from a mean of 9.4 to 8.6 mg/dl. The 
parathormone increased from 9 + 3 to 18 + 8 pmol/1. This
was significant as a group, but in some individuals there 
was no increase in parathormone. In two of these 
patients, 1,25 dihydroxycholecalciferol levels were 
measured and they remained undetectable despite a fall in 
calcium and an increase in parathormone. In two other
patients, phosphate was removed from the total parenteral 
nutrition solution, but the 1,25 dihydroxycholecalciferol 
levels did not increase. In another two patients, both 
calcium and phosphate were removed from the solution for 
10 days and there was still no rise in the 1,25
dihydroxycholecalciferol levels. Thus, these patients
with normal renal function had suppression of the T, 25
dihydroxycholecalciferol production, which was not 
dependent on serum parathormone, calcium or phosphate.
In a study of seven patients receiving total parenteral
nutrition, De Vernejoul et al.(91) also found low bone
formation. The patients had intermediate levels of serum
aluminium of 52.4 + 38.8 ug/1 (1.9 + 1.4 umol/1). The
bone aluminium was not elevated in cortical biopsies (11.7 
v 9-4 ug/g in patients with osteoporosis) and aluminium 
staining was negative. The 1,25 dihydroxycholecalciferol 
levels were normal and parathormone were normal in five 
and elevated in two.
In a recent study of patients on total parenteral
nutrition that had not been contaminated with aluminium,
Lipkin et al.(92) demonstrated a spectrum of disease. 
While the bone formation rates were decreased in patients 
with high or intermediate aluminium exposure, the bone 
formation in the patients without aluminium exposure were 
normal in four of six cases. Thus, total parenteral 
nutrition per se does not result in low bone formation.
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Follow up studies in patients whose total parenteral 
nutrition solutions were changed to amino acids have shown 
that the patients symptoms improved within several weeks. 
In one patient the bone biopsy taken 3.5 years later still 
had a positive aluminium stain, but it had decreased from 
77% to 17% of the surface. The tetracycline labels showed 
good formation in cortical bone, but not trabecula bone. 
After another year the bone formation was normal, and 
aluminium stain had vanished (88). Six other patients
were studied one to two years after changing to amino 
acids, and bone biopsies were normal (93). Thus, when 
aluminium loading is discontinued, these patients with 
normal renal function can slowly eliminate aluminium, even 
from stores in bone.
The casein hydrolysate that was used in total parenteral 
nutrition patients contained about 2000 ug/1 (74.1
umol/1) of aluminium. This is no longer used in clinical 
practice, but recently other intravenous solutions have
been found to contain appreciable levels of aluminium.
The total parenteral nutrition solutions used in France 
(88) had levels of 94 ug/1 (3.5 umol/1) of aluminium with 
phosphate solutions containing up to 3645 ug/1 (135 
umol/1).
Sedman et al.(94) found that infants who had been 
receiving intravenous solutions had increased plasma 
aluminium levels of 36.7 ug/1 (1.4 umol/1) compared with
5.2 ug/1 (0.2 umol/1) in control infants and increased 
bone aluminium levels of 20.2 ug/g compared to 2.0 ug/g. 
Several components of the intravenous solutions were found 
to have high aluminium levels including phosphate salts, 
calcium salts, albumin and heparin. Similar levels of 
aluminium contamination of intravenous fluids have 
recently been reported with typical solutions for
parenteral nutrition containing up to 3^00 ug/1 (125 
umol/1) (61) (95).
albumin
Albumin was first implicated as a potential source of 
parenteral aluminium intoxication in 1978 when Elliott et 
al.(8) failed to treat dialysis encephalopathy by 
plasmapheresis because of unexpected aluminium
contamination of the protein replacement solution. This 
important source of aluminium contamination was largely
ignored at this time, presumably because of widespread 
interest in dialysate fluid contamination and its toxic 
effects on patients with renal failure.
Seven years later Milliner et al.(96) found a transient 
increase in plasma aluminium concentration and elevated 
urinary aluminium in a patient with normal renal function, 
undergoing plasma exchange with aluminium contaminated 
albumin. The patient received 1.2 mg of aluminium and his 
plasma aluminium concentration rose to 121 ug/1 (^.5
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umol/1), and then declined. The urinary aluminium
excretion was 880 ug (33 umol) over 72 hours. There was 
no associated bone pathology. Several commercial
preparations of albumin were screened and Milliner et 
al.(97) reported widespread contamination of albumin 
solutions. They suggested that the albumin solutions were 
contaminated during the manufacturing -process.
Maher et al.(98) reported high plasma aluminium 
concentrations following intravenous albumin infusions in 
a patient receiving haemodialysis. They concluded that 
aluminium loading due to intravenous treatment was likely 
to be of particular importance in patients with renal 
impairment requiring prolonged parenteral nutrition, 
frequent albumin replacement treatment, or plasmapheresis.
Elevated plasma aluminium levels have been reported in 
patients receiving chronic intermittent plasma exchange
(99) and also during single plasma exchange procedures
(100). Thus, the potential toxicity particularly in 
patients with impaired renal function is again 
highlighted.
Contamination of albumin solutions with aluminium is now 
recognised in most products available throughout the world 
(97)(99)( 101 ) . Different sources of aluminium in albumin 
solutions have been implicated such as depth filters, 
filter aids, treatment of plasma with aluminium hydroxide
51
used for absorption of coagulation factors, and steel 
containers used during the manufacturing process 
(97)(102). Manufacturers of albumin solutions have until 
recently neglected this problem because of the lack of 
evidence of toxicity related to aluminium contaminated 
albumin.
1.2.iv MECHANISM OF ALUMINIUM TOXICITY 
Neurotoxicity
The distribution of aluminium in serum and its binding by 
proteins has been investigated by a number of workers 
using a variety of techniques. The latter have included 
ultrafiltration , (103) (10*1) dialysis (50) ( 105 ) (106) and gel 
chromatography (107). The evidence available from these 
studies is consistent with the view that approximately 80% 
of aluminium in serum is protein-bound and appears to be 
associated with transferrin or possibly albumin (108)
(109). The remaining 20% appear to be in the form of 
colloidal complexes. Citric acid and condensed phosphates 
in a pH range 2 - 6  form strong complexes with aluminium
(110).
Transferrin is now considered to be the major aluminium 
transport protein ( 108)( 109)( 1 1 1 ) and it is probable that 
it plays a critical role in the delivery of aluminium to 
tissues such as bone and brain.
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It is not clear why these tissues, and in particular 
brain, should be affected and this has been the subject of 
considerable research. It is possible that genetic 
defects may facilitate entry of aluminium into the brain. 
Another proposal (112) is that the extremely low aluminium 
flux into cells and across the blood-brain barrier may be 
the key. These processes depend on transferrin loading 
and transferrin receptor density, so that short-lived 
cells, unlike the long-lived neurones, may not be able to 
accumulate toxic levels of aluminium.
The mechanism by which aluminium acts as a neurotoxin has 
not been clearly defined. There are a number of potential 
sites at which aluminium may exert its neurotoxic action 
and these include protein synthesis, axonal transport and 
neurotransmitter related events (113). It has been 
demonstrated that aluminium acts as a neurotoxin by 
inhibition of dihydropteridine reductase resulting in a 
reduction of the brain content of tetrahydrobiopterin, 
tyrosine and neurotransmitters (114)(115). Conversely, it 
has been shown that reduction of aluminium in brain 
preparations from patients with Alzheimer's disease 
increases the synthesis of tetrahydrobiopterin (116).
The neurotoxicity of aluminium alternatively may involve 
alterations in the major post-synaptic enzymes of 
cholinergic neurotransmission.
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It has also been reported that aluminium increases the 
permeability of the blood brain barrier to neuropeptides 
and to some non-peptide substances (117). In exerting 
this action aluminium appears to act directly to enhance 
the mechanism by which a substance normally penetrates the 
blood-brain barrier. It does not disrupt the barrier or 
increase permeability by enhancing pinocytosis or 
leakiness.
Bone disease
The type of osteomalacia that is associated with an excess 
of aluminium is unresponsive to treatment with either 
Vitamin D or its biologically active metabolites. The 
mechanism for the disordered bone formation induced by an 
excess of aluminium remains to be clarified. It may 
involve a disturbance either in the formation of calcium 
apatite crystals or in the actual bone mineralization 
process. It has been proposed that aluminium might have a 
different effect at varying bone concentrations with 
inhibition of mineralization at low concentrations and at 
higher concentrations a toxic effect on osteoblasts (118). 
There is also some evidence from in-vitro studies which 
suggests that aluminium may affect the activities of the 
bone enzymes acid and alkaline phosphatase and modify 
their response to parathyroid hormone and 1,25 
dihydroxycholecalciferol (119).
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Aluminium forms a complex with citrate that is a potent 
inhibitor of bone mineralization and retards the growth of 
calcium phosphate crystals in vitro. Thomas and Meyer 
(120) proposed that in patients with chronic renal failure 
the aluminium concentration reaches that which is required 
for the formation of the aluminium-citrate complex and 
that the action of the complex as a crystal poison could 
account for the failure of bone mineralization. Since 
albumin solutions contain the anticoagulant adenine- 
citrate-dextrose phosphate, the formation of the aluminium 
citrate complex is facilitated and this source of 
parenteral aluminium contamination may represent one of 
the most toxic forms of aluminium poisoning.
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1.2.V PLASMA EXCHANGE
Plasma exchange was first performed by Fleig in 1910 (121) 
as a method of removing toxic substances from the blood. 
He used isotonic spa water as the replacement fluid and 
reported substantial clinical improvement. It is now 
common practice to infuse plasma or albumin to replace 
part or all of the lost plasma protein. The exchange of 
large volumes of plasma became possible with the 
introduction of cell separators. The first cell separator 
(122) consisted of a rapidly rotating conical vessel into 
which blood was drawn. The blood became separated into 
layers of red cells, leucocytes, platelets and plasma, so 
that in principle it was possible to harvest any
particular fraction of the blood, although in practice 
satisfactory yields only of red cells or plasma could be 
obtained. Several modifications of this early design took 
place but the introduction of the continuous flow cell 
separator has formed the basis of present-day practice. 
In the IBM Separator,(123) blood is fed into a rapidly 
revolving bowl in which red cells, leucocytes, platelets 
and plasma separate into layers (figure 1.2). Any layer 
can be removed whilst the remainder of the blood is 
continuously returned to the donor. Most modern day cell 
separators have the advantage of using a totally
disposable pathway and centrifuge bowl.
There are certain conditions in which plasma exchange has
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Figure 1.2 DIAGRAM OF A CONTINUOUS-FLOW BLOOD CELL 
SEPARATOR BOWL.
Blood is fed into the bottom of the motor and separates 
into layers, each of which can be collected continuously 
through the appropriate channel.
Taken from Mollinson.
(124)
been shown to be of definite benefit, namely the 
hyperviscosity syndrome, cryoglobulinaemia, myasthenia
gravis, hypercholesterolaemia, and thrombotic
thrombocytopenic purpura. There are also many conditions 
in which suggestive evidence of the value of plasma 
exchange has been obtained but in which it will be 
impossible to reach definite conclusions until controlled 
trials of treatment have been carried out. These 
conditions may be considered under the following headings 
(124).
1. Removal of antibodies
a) Alloantibodies, e.g. anti-Rhesus in pregnant women.
b) Autoantibodies, e.g. myasthenia gravis, Goodpastures 
syndrome.
2. Removal of inflammatory mediators.
3. Removal of exogenous toxins, e.g. paraquat poisoning.
4. Removal of excess plasma constituents, e.g. 
paraproteins, low density lipoproteins.
Since albumin is used as the replacement fluid, a 
previously unrecognised hazard of plasma exchange in these 
conditions is aluminium toxicity particularly in those 
patients on chronic intermittent plasma exchange. This
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risk is greater in patients with impaired renal function.
Plasma exchange has been shown to be of value in patients 
with rapidly advancing renal failure due to crescentic 
nephritis caused by anti-glomerular basement membrane 
antibodies(125) or by immune complexes (126) and in 
chronic forms of progressive glomerulonephritis such as 
mesangiocapillary glomerulonephritis (MCGN) or idiopathic 
membranous nephropathy (IMN) (127). Since these patients 
may receive plasma exchange for periods varying from 
several months to years (125)(127) it is possible that 
considerable loading of parenteral aluminium via albumin 
solutions occurs. Features of aluminium toxicity have not 
been previously described in this group of patients.
CHAPTER 2.
METHODS
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2.1 ALUMINIUM AND TRACE METAL ASSAY
2 .1 . i GENERAL CONSIDERATIONS
Clinical and other biochemical studies of aluminium and 
trace metals are dependent on the availability of accurate 
and precise analytical methods. All biological specimens 
are complex mixtures of a multitude of organic and 
inorganic constituents, making the detection of a true 
constituent, such as aluminium extremely challenging.
During the last decade reports of aluminium toxicity have 
lead to a search for a sensitive, reliable and simple 
method to measure aluminium in biological samples, both at 
toxic and physiological concentrations. Applicable
methods include qualitative chemical staining
techniques ,( 128 )( 129 ) X-ray microanalysis,(50)( 130)( 131 ) 
secondary-ion mass spectroscopy and laser microprobe mass 
analysis,(132) quantitive neutron activation, (1 3 3) 
(13*0 (135) inductively coupled plasma atomic emission
spectrometry ( 136)( 137 ) and electrothermal furnace atomic 
absorption spectrometry. ( 138) ( 139) ( 140) The latter two 
single element methods have also been modified to provide 
multi-element profiles of biological fluids (141).
In this study the method used for the quantitative 
determination of aluminium, chromium and manganese was 
electrothermal furnace atomic absorption
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spectrophotometry, while simultaneous multi-element trace 
analysis of nickel, iron, magnesium, zinc, copper and 
selenium was determined by inductively coupled argon 
plasma mass spectrometry (141). These methods offer the 
best sensitivity, selectivity and simplicity.
2.1.ii ALUMINIUM, CHROMIUM AND MANGANESE MEASUREMENTS
Electrothermal atomic absorption spectrometry
In this technique the sample is placed in a graphite tube
furnace (carbon rod) mounted in the light path of the
spectrophotometer. The source of light is an aluminium, 
chromium or manganese hollow cathode lamp which emits a 
characteristic wavelength. First the graphite tube is 
heated with a direct current to dry the sample at a 
low temperature (80 C to 300°C) then the sample is ashed
(700°C to 1300°C) to destroy organic matter or matrices
and burn off inorganic species that may interfere and 
finally the temperature is quickly raised to 2,750°C and 
the metal under analysis vaporises and absorbs the light 
being passed through the graphite tube. The absorption 
signal is a sharp peak, the height or area of which can be 
related to the amount of metal present. Microlitre (2 to 
100 ul) samples are introduced into the furnace by 
injection with an auto-sampler and the sample is dried, 
ashed and atomised.
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Aluminium:
Aluminium assays on plasma, urine, albumin, other blood 
products and bone were carried out by electrothermal 
atomic absorption spectrometry on a Perkin- Elmer (PE) 
2280 spectrometer, equipped with a Perkin-Elmer HGA 500 
Carbon furnace and AS-1 auto sampler with a model 56
recorder as detailed by Gardiner et al.(138).
calibration
Calibration was carried out using aqueous standards and 
this has been reported as adequate for the determination 
of aluminium in plasma, serum and urine ( 138)( 139)( 140).
sensitivity
The detection limit as measured by the signal noise
obtained from a 2.2 umol/1 aqueous standard was 0.13
umol/1.
accuracy and imprecision
"In-house” pooled samples of plasma, urine and bone were 
used as internal quality control. Plasma samples 
circulated by the Robens Institute, The University of
Surrey were used as external quality control checks.
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Plasma spiked with aluminium (+3*7 and +7.4 umol/1) showed 
a mean recovery of 95%. Imprecision was evaluated by 
monitoring variations between repeated measurements and the 
coefficient of variation was 2.9% at a concentration of 
10 umol/1.
Chromium and Manganese:
Manganese and Chromium assays on plasma, urine albumin and 
other blood products were carried out by electrothermal 
atomic absorption spectrometry using the same instrumentation 
as for aluminium.
calibration
Calibration was carried out using aqueous standards
( 142)( 143).
sensitivity, accuracy and imprecision
Manganese-: Detection limit was 2 nmol/1.
Coefficient of variation was 3*7% at a 
concentration of 84 nmol/1.
Chromium : Detection limit was 10 nmol/1.
Coefficient of variation was 6.1% at a 
concentration of 38 nmol/1.
The accuracy of the procedure was assured by a satisfactory 
interlaboratory comparison of pooled 4.3% human albumin
2 .1. iii TRACE METAL MEASUREMENTS
Inductively coupled argon plasma mass spectrometry
This new method has only relatively recently been applied 
to clinical samples. The instrument is a combination of 
two well-proven techniques in' which a high temperature 
argon plasma (8000°C) is produced by inductive electrical 
heating. Liquid samples are sprayed into the plasma via a 
nebulizer.
Rapid heating dissociates all compounds and produces ions 
for each element present. These ions are collected from 
the central plasma through a special aperture into a 
quadraple mass analyser, in which the number of counts for 
each ionic mass is measured.
Nickel, Manganese, Iron, Zinc, Copper and Selenium:
Nickel, Magnesium, Iron, Zinc, Copper and Selenium assays 
were obtained using a Plasma Quad (VG Elemental, Winsford, 
Cheshire, UK).
calibration
Calibration in a semi-quantitative scan mode was carried 
out using Indium (25 ng/ml) as an internal standard or by 
use of appropriate multi-element aqueous standards (141).
sensitivity
The detection limit was less than 10 nmol/I for all elements 
assayed.
accuracy and imprecision
A within-batch imprecision of less than 5% and a between- 
batch imprecision of less than 10% was obtained for all the 
metals as reported by Lyon et al (141). Accuracy has been 
shown to be good by use of external reference materials and 
direct comparison of results with established atomic 
absorption spectrometric methods (141).
2.1.iv SAMPLE COLLECTION
Sample contamination is a serious problem because of the 
ubiquitous nature of aluminium and trace metals and great 
care was taken with collection as follows:
Plasma
Blood was collected after venepuncture with a stainless 
steel needle into a plastic syringe via a venflon plastic 
cannula. The samples were then immediately transferred to 
an aluminium - free plastic tube with sodium citrate as the 
anticoagulant. Plasma was separated within 20 - 60 minutes 
and aliquoted into aluminium-free plastic containers which 
were stored at 4 -C. prior to analysis.
66
Urine
Twenty-four hour urine specimens were collected in aluminium- 
free plastic containers which had previously been cleaned 
with nitric acid. A 10 ml aliquot was transferred to a 
sterile polypropylene tube which was stored at 4 C.
Bone
Samples for aluminium analysis were placed in an aluminium- 
free plastic container and stored at room temperature. 
Prior to analysis the bone was dissolved in nitric acid.
Albumin
2ml aliquots were removed from each bottle of 5% or 20% 
albumin solution or blood product using a stainless steel 
needle and plastic syringe. This was immediately
transferred to an aluminium-free plastic container and 
stored at 4°C. prior to analysis.
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CHAPTER 3-
DETERMINATION OF THE DEGREE OF ALUMINIUM AND 
TRACE METAL CONTAMINATION OF ALBUMIN SOLUTIONS AND 
BLOOD PRODUCTS ISSUED FOR TREATMENT OF PATIENTS
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3.1 STUDY DESIGN
Aluminium
Samples were taken from at least three batches (range 3 
10) of all the available blood products which were present 
in the Blood Transfusion Laboratory of the Royal 
Infirmary, Glasgow.
The majority of the products were manufactured by the 
Protein Fractionation Centre of the Scottish National 
Blood Transfusion Service. Other manufacturers whose
products were tested include Armour Pharmaceuticals, 
Speywood Laboratories, Wrexham, Immuno A.G. Vienna, 
Austria, Hoechst UK and the Protein Fractionation 
Laboratory, Oxford.
Aluminium concentrations were determined by electrothermal 
atomic absorption spectrometry using a method developed 
for measurement of plasma aluminium (138). The blood 
products studied were albumin solutions (5% and 20%) from 
three different manufacturers, fresh frozen plasma, 
cryoprecipitate, human factor IX Concentrate, anti- 
haemophilic factor VIII, porcine factor VIII, anti­
inhibitor coagulant complex (F.E.I.B.A.) human
immunoglobin preparations (for intravenous and
intramuscular use) and antithrombin III concentrates.
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Trace Metal Contamination of Albumin Solutions and Blood 
Products
Using electrothermal atomic absorption spectrometry 
chromium and manganese concentrations were determined in 
blood products produced by four manufacturers (Table 3. )^. 
Inductively coupled argon plasma mass spectrometry was
used to determine the concentrations of nickel, iron,
magnesium, zinc, copper and selenium in samples of single
batches of albumin solutions (5% and 20%) from three
different manufacturers (Immuno, Scottish National Blood 
Transfusion Service, Armour).
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3.2. RESULTS
All of the albumin solutions contained significant amounts 
of aluminium compared to normal plasma (aluminium <0.5 
umol/1). The concentrated albumin solutions (20%)
contained more aluminium (Immuno 46.5 + 1.9 umol/1,
Scottish National Blood Transfusion Service (SNBTS) 30.5 + 
1.5 umol/1, Armour Pharmaceuticals 20.4 +_ 1.2 umol/1) than 
4.3% albumin solutions (Immuno 9.1 +_ 1.4 umol/1 Scottish
National Blood Transfusion Service 18.3 +. 2 umol/1 Armour 
pharmaceuticals 6.7 +.1.4 umol/1) see Table 3-1. All the 
factor VIII concentrates and immunoglobulin preparations 
contained significant aluminium levels whereas human 
factor IX and antithrombin III concentrates contained 
aluminium levels within the normal range (Table 3.2).
Increases in concentration of ten fold to several thousand 
fold the normal reference values were noted for chromium, 
manganese, nickel and iron. There were also marked 
depletions of essential trace elements such as magnesium, 
zinc, copper and selenium (Table 3.3, Table 3.4).
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3.3 DISCUSSION
There was significant contamination of all the albumin
products with aluminium. Similar levels of aluminium 
contamination were found by several authors when most of
the products currently available were analysed (94) (95)
(97) (98) (99). The aluminium concentrations in products
from a single supplier were similar and this suggests that 
each manufacturing process might have its own specific 
source of aluminium. There is little doubt that metal 
contamination occurs during the production cycle since 
human plasma, which is the starting material, is low in 
aluminium. In addition there is no evidence for aluminium 
contamination from aluminium bottle caps or from distilled 
water from distillation and sterilization plants (144).
Other blood products including coagulation factors such as 
factor VIII, F.E.I.B.A. (anti-inhibitor coagulant complex) 
as well as immunoglobulin preparations have similar 
concentrations of aluminium contaminations to albumin 
solutions. These other potential sources of aluminium 
toxicity seem to be little recognised since there are no
clinical observations of acute or chronic aluminium 
toxicity reported in spite of the widespread use of these 
blood products. A possible explanation is that the 
majority of patients, namely haemophiliacs, who receive
these products have normal renal function and therefore 
excrete most of the aluminium. Additionally the volume of
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product infused is lower. However, the long term 
neurotoxic effects of exposure to aluminium remains a 
potential problem, especially for those with some degree 
of renal involvement.
Apart from aluminium there is a widely varying trace metal 
contamination of albumin and colloid solutions. When the 
results for various protein products are compared with the 
normal plasma reference range, increases in concentration 
10-fold to several 1000-fold are noted for chromium, 
manganese, nickel and iron. There are marked depletions 
of essential trace metals such as magnesium, copper, zinc 
and selenium.
Manufacturers and clinicians were unaware of this problem 
until it was reported recently (101). It is not uncommon 
for large volumes of albumin and colloid solutions to be 
used in the treatment of patients with renal impairment 
who are not able to excrete the infused load of 
potentially toxic metals. The toxicity of aluminium is 
now well established, but the clinical significance of the 
repeated infusion of small amounts of other metals is at 
present quite unknown. In a survey of several albumin 
preparations Leach et al. (145) noted considerable nickel 
contamination and pointed out various potential adverse 
effects, including exacerbation of allergies. It is 
possible that a reaction to trace metals, such as nickel, 
might explain the attacks of rigors, shivering and
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hypotension which some patients experienced while 
undergoing plasma exchange, with the most heavily 
contaminated albumin solutions. It is interesting that 
these reactions occurred more frequently when contaminated 
Scottish National Blood Transfusion albumin was used as 
the replacement fluid, whereas the Immuno albumin and 
Haemaccel solutions did not appear to ' cause these 
problems. These clinical observations have also been made 
by other clinicians who treat patients with regular plasma 
exchange (146) and this matter warrants further 
investigation.
In addition to problems which exist with aluminium 
contamination of albumin and colloid solutions, there are 
also marked depletions of trace elements, such as 
magnesium, zinc, copper and selenium. An acute decrease 
of serum copper, selenium and zinc concentrations was 
reported immediately and found to last for several weeks 
following plasma exchanges with albumin solutions 
(147)(148). There were no symptoms suggesting plasma 
exchange-induced trace element deficiency in these 
patients. However in certain clinical situations where 
plasma exchange may be repeated once or twice per month 
for several years, chronic depletion of body stores of 
these trace elements may occur. Recent reports indicate 
an association between selenium deficiency and an 
increased incidence of coronary artery disease, and those 
patients on long-term plasma exchange may be at risk
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(149). The losses during plasma exchange are obviously 
related to the elemental composition and content of the 
replacement fluid and might be controlled by using fluids 
where trace elements are present in similar concentrations 
and in the same chemical form as in normal plasma.
CHAPTER 4.
ALUMINIUM RETENTION AND ALUMINIUM BONE DISEASE 
IN PATIENTS RECEIVING PLASMA EXCHANGE WITH CONTAMINATED
ALBUMIN
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4.1. STUDY DESIGN
4 .1. i PATIENTS
Eight patients (five males, three females), aged 21 to 74 
years, undergoing regular plasma exchange (two months to 
seven years) for a variety of disorders were studied 
(Table 4.1). Two patients had mesangiocapillary
glomerulonephritis and one had IgA nephropathy. Three had 
Waldenstrom’s macroglobulinaemia, one had Guillain-Barre 
Syndrome and one had myasthenia gravis. Patients were 
divided into two groups, those with poor renal function, 
Group 1 (Creatinine Clearance < 50 ml/min and those with 
adequate renal function, Group II (Creatinine Clearance > 
50ml/min) (Table 4.2). Two of the patients (MC, TS) in
Group 1 had suffered intermittent bone pain while 
receiving plasma exchange.
4 .1 . ii PLASMA EXCHANGE REGIMEN
On each occasion 2.8 litres of albumin solution were 
exchanged. All Group 1 patients received 4.3% Human
Albumin (Immuno AG Vienna, Austria), during the exchange 
procedure which was carried out using an IBM Continuous 
Flow Cell Separator. Group II patients were plasma
exchanged with 4.3% albumin solution (Protein 
Fractionation Centre, Scottish National Blood Transfusion 
Service, Edinburgh, UK), using a Fenwall Continuous Flow
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4.1. iii METABOLIC BALANCE STUDY
During each plasma exchange, samples of all the 
replacement albumin solutions infused and all plasma 
removed from the patients were- analysed for aluminium. In 
patients undergoing a single plasma exchange, plasma 
aluminium concentration was measured before exchange and 
at 0, 24, 48 and 72 hours. Twenty-four hour urinary
aluminium excretion was measured before and for three 
consecutive days after the procedure.
In those patients receiving 2 or 3 consecutive plasma 
exchanges, additional measurements were made of plasma 
aluminium concentration before and after completion of 
each exchange, and twenty-four hour urinary aluminium 
output was measured following each exchange.
4.1.iv CALCULATIONS
Total Aluminium Output
This was derived from the known volume of albumin infused 
at each exchange or series of exchanges, and the measured 
aluminium concentration of that solution.
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Aluminium Removed in Plasma During Exchange
This was derived from the volume of plasma removed from
the patient and the measured aluminium concentration of 
that solution. This quantity was then expressed as a 
percentage of the total infused aluminium load.
Aluminium Excreted in Urine
The daily output of aluminium was calculated from the 
urine volume and the measured urinary aluminium
concentration. The amount excreted over the three day 
period was then determined and from that total three times 
the pre-exchange daily urine aluminium output was
subtracted to allow for base-line urine aluminium
excretion. The net urine aluminium excretion was then
expressed as a percentage of the total infused aluminium
load.
Recovery of Infused Aluminium
This is the sum of the aluminium excreted in the urine (3
days) and the aluminium removed in plasma, expressed as a
percentage of the total infused load.
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Faecal Aluminium
Faecal aluminium was not measured in the balance studies 
because only a very small proportion of an injected dose 
of aluminium would be normally be excreted in the faeces 
(74) (150).
4 . 1 . v DETECTION OF PATIENTS WITH BONE ALUMINIUM
OVERLOAD 
Bone Biopsies
Four patients (MC, JM, TS - Group I and IM - Group II), 
each underwent two bone biopsies of the anterior iliac 
crest after tetracycline double labelling. Bone biopsies 
were performed using a Meuniere needle providing a core of 
8mm in diameter. On the first biopsy histomorphometric 
analysis of undecalcified sections was performed after 
fixation in four percent neutral buffered formaldehyde 
and embedding in methacrylate (48). The presence of 
aluminium in bone was shown by a staining procedure using 
aurine tricaboxylic acid (Aluminon). The bone aluminium 
content (ug/g dry weight) was determined on the second 
bone biopsy from each patient.
Histomorphometric Assessment:
bone resorption and formation
This was assessed with a Zeiss One integrating eye piece, 
by line intersect measurement of total osteoid surface 
(TOS), active osteoid surface (AOS), total resorption 
surface (TRS), an active resorption surface (ARS) on four 
representative eight micrometer sections stained with a 1 % 
toluidine blue (48). These measurements gave an
indication of the degree of secondary hyperparathyroidism.
mineralisation
This was assessed by measuring the extent of calcification 
fronts along the osteoid surfaces on four representative 
stained eight micrometre sections (1% toluidine blue, 5% 
(ETA) and by counting the maximum number of bright osteoid 
lamellae (MNOL) visualised with polarising microscopy.
Desferrioxamine Mobilization Test
To further demonstrate the extent of aluminium retention a 
desferrioxamine infusion was given to five patients (MC,
JM, TS, Group I and IM, SW, Group II) (151). Four
grammes of desferrioxamine were infused in 250ml of 5% 
dextrose over a four hour period. This was carried out at
least 2 weeks after the last plasma exchange. Plasma
Rr
aluminium concentrations were measured before, and 48 
hours after the infusion of desferrioxamine. The 24 hour 
excretion of aluminium in urine was measured before and 
for three consecutive days after the infusion.
The amount of aluminium excreted in urine over those three 
days following the tests was calculated and three times 
the pre-test urine aluminium daily output subtracted to 
give a net urine aluminium mobilised (Appendix II).
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4.2. RESULTS
4 .2.i ALBUMIN SOLUTIONS
Each of the albumin solutions tested contained a high 
concentration of aluminium relative to normal plasma (<0.5 
umol/1). Albumin produced by the Scottish Blood
Transfusion Service Protein Fractionation Centre contained 
twice as much aluminium (18.3 umol/1) as Immuno human 
albumin (9.1 umol/1) (Table 3.1).
4.2.i i BALANCE STUDIES
Patients received an intravenous load of aluminium which 
varied from 11 umol to 123 umol (Table 4.2). Three
patients (MC, JM and IM) were each studied on two occasions 
separated by one month. Patient IM received a similar 
load of aluminium on each occasion, while patients MC and 
JM received different loads. The proportion of aluminium 
excreted in the urine, that removed during plasma exchange, 
and the overall retention were similar for each patient on 
the two occasions.
The total amount of aluminium retained by the patients was 
dependent upon their renal function. As can be seen in 
Table 4.2, those with a creatinine clearance of less than 
50 ml/min retained 60-74% of the infused aluminium. In 
Group II (creatinine clearance >50 ml/min) those patients 
with a creatinine clearance of greater than 70 ml/min
85
Ta
bl
e 
4.
2 
- 
ME
TA
BO
LI
C 
BA
LA
NC
E 
ST
UD
IE
S:
 
AL
UM
IN
IU
M
H U j
j  co
a. Ed
os o
CJ PS
o co
Ed Ed
CJ CJ
Ed
CO
<
CJ
vo o • • n  o • • VO o• o o 1 • VO no cn 0-43- o VO OJ o • •
vo vo vO 0- C- VO 43- VO on o VO
43-43- O =T
• • • •
4 3- n  on n
in
in
cn eg c- 
• •
oj
cn on
in
on
in
o CT\ 
• •
in in
on o
t •
m on
in co
on OJ
1- o 0J o OI • • • i
co cn Ov 0J n
0J T- n 0Jr— CO
co 43-
onvo 
oj on
oj o co
cn cn 
on o oon
0J o vo o
in cn on
n n  . vo OJ
T-
vocn
oo c-oj in t-in in cn OJ
* *
cj o  
£ I
S i
4-5
Co
E
0
Co
r—1
2L0
4-5
c
•H
03
Co•H
CO
reooo
844
co
T30
•HTJ344
CO
CO
44
c
0
•H
44
&0-
only retained upto 6% of the infused aluminium load.
The influence of deteriorating renal function on the 
urinary output of aluminium is illustrated in Figure 4.1 
which also shows that the amount of aluminium removed in 
the "plasma bag" was a small proportion of the input.
4.2.i i i PLASMA ALUMINIUM CONCENTRATIONS
The patients with a creatinine clearance of less than 50 
ml/min had a tendency for their plasma aluminium 
concentrations after exchange to be higher than those with 
adequate renal function (Table 4.3).
However plasma aluminium concentration did not reflect the 
extent of aluminium retention in any given patient.
4.2.iv HISTOMORPHOMETRY AND BONE ALUMINIUM CONTENT
The three patients with poor renal function had raised 
concentrations of aluminium in their bone biopsy 
specimens. (Reference value < 10ug/g dry weight bone) 
(Table 4.4).
Patient MC, after 53 months on plasma exchange had 38 ug 
of aluminium per gramme in bone and showed increased bone 
formation and resorption indicative of moderately severe
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secondary hyperparathyroidism. Bone mineralization was 
normal and no aluminium was demonstrable histochemically 
at the calcified bone osteoid interface, although 
aluminium lines were present within calcified bone due to 
previous deposition. This patient complained of
intermittent bone pain.
Patient JM after six months of weekly plasma exchange had 
70ug of aluminium per gramme in bone and showed normal 
bone turnover, no impairment of mineralisation and minimal 
deposition of aluminium at the calcified bone osteoid 
interface.
Patient, TS after 84 months on plasma exchange had 63ug of 
aluminium per gramme in bone and showed extensive 
deposition of aluminium at the calcified-bone osteoid 
interface associated with a marked reduction in the extent 
of calcification fronts indicating defective
mineralization. Osteoid seam thickness was not increased, 
therefore the appearances did not amount to frank 
osteomalacia. The changes of moderate secondary
hyperparathyroidism were superimposed. This patient
complained of intermittent bone pain.
Patient IM after 27 months on plasma exchange had 8ug of 
aluminium in bone, and a normal bone biopsy with no 
histologically stainable aluminium.
87
4.2.V DESFERRIOXAMINE MOBILIZATION TEST
The results obtained for the five patients are shown in 
the Table (4.5). The values for plasma aluminium before 
and after infusion are given and the difference ( a plasma 
aluminium) at 48 hours calculated. Similarly the pre­
infusion- and post-infusion urinary aluminium excretions 
are given and the difference ( a urine aluminium) is
calculated.
The bone content of aluminium for MC,JM,TS and IM are 
shown alongside for comparison. Patients MC and JM for 
whom there was definite evidence of aluminium retention
showed the greatest increases in both plasma aluminium
concentration and in urinary aluminium excretion after 
desferrioxamine.
Patient TS who showed the greatest increment in plasma 
aluminium had been treated for the longest time (84
months). Urine samples for this patient were thought to 
be contaminated prior to analysis.
Patients IM and SW in whom there was less aluminium 
retention showed much smaller changes in plasma and urine 
aluminium after desferrioxamine.
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4.3. DISCUSSION
During experimental intravenous loading with aluminium, 
renal clearance is extremely efficient (152). It is not 
thought likely that endogenous secretion of aluminium into 
the gastrointestinal tract is an important route of 
elimination (150). Faecal aluminium output mainly
reflects unabsorbed dietary aluminium. Therefore,
measurement of faecal aluminium excretion was not 
attempted in the balance study. Of the eight patients who 
were being treated by plasma exchange for a variety of 
immunological disorders, four patients with severe renal 
impairment retained 60-70% of the aluminium infused during 
plasma exchange; while three patients with normal renal 
function retained very little aluminium (up to 6%). One 
patient with moderate renal impairment (creatinine 
clearance of 55 ml/min) retained 42 - 60% of the infused
aluminium. A bone specimen obtained from this patient had 
a normal bone aluminium content and no stainable 
aluminium.
Transiliac bone biopsy specimens taken from three of the 
patients with high aluminium retention and poor renal 
function, showed an elevated bone aluminium content and 
histologically stainable aluminium. Although none of the 
patients had ’’classical” aluminium related osteomalacia 
and the pattern of aluminium staining differed amongst the 
three patients, these findings can be explained on the
89
basis of variations in bone turnover, the duration and 
frequency of plasma exchange and the total exposure of 
sites of bone formation to aluminium throughout the 
clinical history.
Patient MC had histological evidence of florid 
hyperparathyroidism since 1981 and again in the most 
recent bone biopsy. However in the interval following the 
administration of (1 -o* - Hydroxy Cholecalciferol) she was 
biochemically euparathyroid for several years and it is 
considered that the aluminium lines within calcified-bone 
represent heavy deposition of the metal at the calcified 
bone interface during the euparathyroid phase. This 
patient did complain of intermittent bone pain.
The skeleton of patient JM, with normal bone turnover has 
not been exposed to aluminium for a sufficiently long 
period of time to cause major osteodystrophy, although 
there is a build up of aluminium in bone. This patient
received weekly plasma exchanges compared to monthly
exchanges for MC and TS.
Patient TS, with a milder hyperparathyroidism than patient
MC, shows a "mixed” bone disease having a sufficiently low
bone turnover to allow accumulation of aluminium at the 
calcified-bone osteoid interface, yet with sufficient 
turnover to offer a large osteoid surface for uptake of 
aluminium and produce defective mineralisation, but not
90
frank osteomalacia. This patient also complained of 
intermittent bone pain.
The plasma aluminium concentrations measured before and 
after exchange were not an accurate index of aluminium 
retention though there was a tendency for the patients 
with poor renal function to have the highest plasma 
aluminium concentrations immediately after exchange. The 
concentrations observed, however, did not exceed 3-7 umol 
of aluminium per litre which was suggested by Charhon et 
al.(153) as the level at which aluminium deposition in 
bone was probable in patients undergoing haemodialysis. 
These results show that aluminium retention can be present 
at plasma aluminium concentrations well below 3*7 umol of 
aluminium per litre.
Patient IM whose balance studies had shown some retention 
of aluminium is similar to the case reported by Milliner 
et al.(96) who showed that there was no bone biopsy 
evidence of aluminium toxicity in a patient with a normal 
serum creatinine, who had received a total of 83 plasma 
exchanges with aluminium contaminated albumin solutions. 
However the results clearly show that Milliner’s 
conclusion ’’the amount of aluminium delivered by infusions 
of albumin is too small to present a real risk” is an 
overgeneralisation.
Demonstration of aluminium retention requires metabolic
O 1
balance studies and bone biopsy, and cannot be based upon 
observation of plasma aluminium concentrations alone.
Since none of the patients were being treated by 
haemodialysis and only one (patient MC) was receiving
aluminium hydroxide as a phosphate binder (the two usual
sources of aluminium in chronic renal failure), it is 
concluded that the aluminium accumulation in their bone
has been due to the administration of aluminium
contaminated albumin.
Although an aluminium 
described effect of 
neurotoxicity is also 
interest in the role 
Alzheimer’s disease 
related to ageing.
Patients given infusions 
receiving up to 10 times 
absorbed from the diet, 
large volumes of albumin 
products) to patients with 
bone disease. There is 
patients could be at 
disease in the long term.
induced osteomalacia is the best 
chronic aluminium toxicity, 
well recognised and there is 
aluminium in the development of 
other degenerative conditions
of contaminated albumin are 
the amount of aluminium normally 
The prolonged administration of 
(or other aluminium contaminated 
renal impairment will result in 
also a possibility that these 
risk of developing Alzheimer’s
of
and
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CHAPTER 5.
STAGES OF MANUFACTURING PROCESS CONTRIBUTING TO 
CONTAMINATION OF ALBUMIN SOLUTIONS AND EFFICIENCY OF 
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5.1. SOURCES OF CONTAMINATION
5 .1 - i INTRODUCTION
In 1978, Elliott et al.(8) showed that albumin solutions 
were contaminated with aluminium. The Protein
Fractionation Centre, Scottish National Blood Transfusion 
Centre, which was the manufacturer of albumin used in the 
patient study of Elliott et al. responded to this report 
and steps were taken to reduce the aluminium. The source 
of the aluminium contamination was thought to be sodium 
hydroxide solutions used during the manufacturing process.
When albumin solutions were tested eight years later 
(Chapter three) there was still significant aluminium 
contamination in most of the albumin solutions available 
for clinical use. Following an initial report on the 
level of aluminium and other trace metal contamination of 
albumin products (101), the various manufacturers of the 
products were advised of the levels of contamination. The 
unanimous response was that the levels of contamination 
reported were too low to be clinically significant. 
Following a second report,(15*0 (Chapter four) showing 
aluminium bone disease in patients with impaired renal 
function receiving albumin solutions, there were several 
responses from manufacturers of albumin solutions 
(155)(156)(157). In these reports there were clear
indications of an attempt to remove or reduce metal
oc:
contamination in albumin solutions.
One of these manufacturers, the Protein Fractionation 
Centre, Scottish National Blood Transfusion Service 
initiated detailed and extensive investigations to 
identify the sources of metal ion contamination. When 
they had successfully identified the sources they then 
evaluated revised procedures intended to reduce and
eliminate contamination.
Acknowledgement: The data in this section was
kindly provided by Mr William
McBey, Protein Fractionation
Centre, Scottish National Blood
Transfusion Service.
5 -1.ii STUDY DESIGN
An outline of the manufacturing process of human albumin 
is shown in figure 5.1. Samples were taken at various 
intermediate stages (A-F) and analysed at the Scottish 
National Blood Transfusion Service by atomic absorption 
spectrometry using a Pye Unicam SP 192 spectrophotometer. 
The concentrations of aluminium, chromium, copper, 
manganese, nickel and zinc were determined in each sample.
Other possible sources of contamination which were studied 
included, sodium hydroxide solutions which are used for pH 
adjustment in the manufacturing process and caprylic acid 
solutions which prevent denaturation of albumin during 
pasteurisation. Stainless steel containers used
throughout the manufacturing plant were also considered as 
a source of contamination and concentrations of the metal 
ions were determined in starting plasma before and after 
storage in a stainless steel container for a period of 
time similar to the time taken for the fractionation of 
albumin from plasma. The glass bottles used for storage 
of sodium hydroxide were also investigated by measuring 
the aluminium concentration in sodium hydroxide after 
storage times from 10 minutes to 24 hours.
Q 7
STAGE A PLASMA
STAGE
STAGE
(POST
STAGE
STAGE
STAGE
PURIFICATION BY COLD-ETHANOL 
FRACTIONATION
ALCOHOL CONTAINING 
ALBUMIN SOLUTION
B
DEPTH FILTRATION (BK9)
BK9)
PRECIPITATION
RESOLUTION
ALCOHOL REMOVAL BY VACUUM 
DISTILLATION
D
DEPTH FILTRATION (EKS/CW03)
E
STERILE FILTRATION 
(0.45u + 0.2u) DURAPORE
F FINAL PRODUCT (ALBUMIN)
A-F: POINTS AT WHICH 
SAMPLES FOR 
TRACE METAL 
ANALYSIS WERE 
TAKEN
Figure 5-1 Flowsheet of plasma fractionation to albumin
5.1. iii RESULTS
Figure 5.2 shows that the concentrations of aluminium, 
nickel, chromium and manganese showed a steady increase 
throughout the process while copper concentrations were 
unaffected and zinc concentrations fell.
The depth filtration (Stage C) was found to be the 
principal cause of increased concentrations of trace 
metals, although the cartridge filters employed for 
sterile filtration Stage (F) resulted in a slight increase 
in the level of aluminium, chromium, nickel and copper.
Sodium hydroxide solutions were contaminated with 
aluminium and most of the metal had leached from glass 
storage containers (Table 5.1).
Caprylic acid contained significant concentrations of 
aluminium, ion and nickel as contaminants.
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Figure 5.2 STAGES AT WHICH METAL CONTAMINATION OCCURS 
DURING ALBUMIN PRODUCTION.
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5.2. REVISED PROCEDURES TO ELIMINATE CONTAMINATION
5.2.i INTRODUCTION
When the major sources of contamination of the 
manufacturing process were identified the Protein 
Fractionation Centre, Scottish National Blood Transfusion 
Service undertook a number of developments to further 
reduce contamination in albumin solutions and other blood 
products.
The filtration processes were modified so that the filters 
were flushed with a carefully selected wash solution 
(Citric Acid, pH3) before the passage of protein to reduce 
metal ion contamination.
The aluminium introduced into sodium hydroxide solutions 
during storage in glass containers was eliminated by 
replacing glass with plastic containers.
Caprylic acid was replaced by sodium caprylate which 
contained no significant amounts of either aluminium or 
nickel. Although the metal ion contamination could be 
reduced by these measures relatively high concentrations 
still remained in the albumin. The beneficial effect of 
ultrafiltration for the removal of both residual ethanol 
and metal ions then evaluated on a pilot scale.
99
Ultrafiltration is a process of selective molecular 
separation. It employs membranes capable of passing 
solutes and solvents of low molecular weight while 
retaining solutes that are above certain specified 
molecular dimensions. Diafiltration is defined as
constant volume ultrafiltration.
5.2.ii STUDY DESIGN
Albumin solution (Stage F Figure 5.1) at pH 6.9 was 
diafiltered against five times its volume of 130 mmol 
sodium chloride using spiral wound cellulose membranes 
(Amicon low absorption YM series with 10,000 daltons 
molecular weight cut off). The resulting albumin
solutions were pasteurised and the product re-analysed for 
metal ion contamination and evidence of protein 
denaturation and ethanol content.
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5 . 2 . iii RESULTS
The diafiltration process removed more than 90% of 
aluminium and manganese, 80% chromium, but only 25% nickel 
from the albumin solution (Table 5.2). The ethanol 
concentration fell exponentially with the volume of 
diafiltration solution (Figure 5.3).
The final pasteurised albumin solutions contained greatly 
reduced metal ion contamination when compared to the 
conventional product (Table 5.3). All quality control
parameters were in the normal range.
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5.3. DISCUSSION
The detailed and extensive investigations undertaken by 
the Scottish National Blood Transfusion Service show that 
depth filters are the principal cause of increased 
concentrations of aluminium and trace metals presumably 
due to selective absorption and desorption taking place 
between the depth filter and the protein solution. These 
depth filters consist of a matrix of self-bonding fibres 
(cellulose) and diatomite, perlite or sand, and are 
therefore a rich source of aluminium and other trace 
metals.
The quantity of aluminium which can be leached from such 
filters into the product is reduced by extensive flushing 
with citric acid before use. The sources of contamination 
of sodium hydroxide solutions and caprylic acid can also 
be readily eliminated.
Despite these processing changes, some aluminium and trace 
metal contamination still occurs during the manufacturing 
process. This residual contamination is leached from the 
large stainless steel storage containers which are used in 
the manufacturing process. Most of the metals can be 
removed using an ultrafiltration procedure, but the small 
retention of metal ions is most likely the result of 
fractional binding to albumin with nickel being bound the 
tightest.
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The results presented show that it is now possible to 
prepare albumin solutions with an aluminium content of 
less than 1 umol/1.
There have also been encouraging reports (97) from other 
manufacturers showing low concentrations of aluminium in 
their products following modifications to their 
manufacturing processes. Armour Pharmaceutical Company 
have carefully evaluated their albumin preparation methods 
and found that the source of contamination was the same as 
the Protein Fractionation Centre, Scottish National Blood 
Transfusion product. A new fractionation protocol which 
also included diafiltration was implemented by Armour. 
With this new process the aluminium concentration in 5% human 
albumin was reduced from 1 108 + 384 (41 _+ 12.9) to 131 +_
20.1 ug/1 (4.9 +. 0.7 umol/1) and the aluminium
concentration in Armour 25% human albumin was reduced to 
738 _+ 81.6 mg/1 (27.3 +_ 3 • 1umol/1) (97). Inspite of these
reductions the level of aluminium in these albumin 
solutions is four to twenty seven times higher than in 
normal plasma.
A recent report shows that the concentrations of aluminium 
in albumin solutions from most manufacturers remain 
unacceptably high (99). It is imperative that these 
manufacturers follow the example of the Protein 
Fractionation Centre, Scottish National Blood Transfusion 
Service and undertake detailed investigations of the
103
manufacturing process and institute the necessary 
modifications to produce albumin solutions which are not 
only free of aluminium but of other trace metals.
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6.1. INTRODUCTION
There is a significant increase in aluminium intestinal 
absorption when citric acid is ingested orally at the same 
time (158). This occurs because the neutral complex of 
aluminium and citrate provides a means by which aluminium 
can pass through membranes. Similarly, the
intraperitoneal administration of citric acid enhances 
urinary aluminium excretion (159). Citrate has been shown 
to be a very effective chelator of aluminium and other 
metals. Citric acid has been proposed as a possible
therapeutic alternative to the use of desferrioxamine in 
the treatment of aluminium toxicity (160).
The ability of citrate to chelate calcium ions makes it a 
most efficient anticoagulant and it is added during the 
collection of whole blood before the plasma is separated 
and then fractionated into albumin and other blood 
products. These products may contain significant amounts 
of citrate, since it is not specifically removed during 
the production cycle.
It is likely that citrate will form complexes with 
aluminium and other trace metal ions present at various 
stages of the fractionation process. This role of citrate 
has not previously been considered by the manufacturers.
In the scientific literature (161) over the last five
years, there has been considerable interest in the
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speciation of trace metals and their interaction with 
citrate.
Citric acid occurs as the tricarboxylate anion, citrate at 
pH 7.H in blood and provides oxygen donor ligands which 
counter the 3+ charge on trivalent ions of the ferric, 
chromium or aluminium type. The carboxylate groups in 
citrate are positioned to make stronger binding possible 
with these trivalent ions compared with other common 
divalent ions such as calcium, magnesium, ferrous copper, 
zinc and manganese. The stability constants give an 
indication of the relative binding strengths of the 
citrate ligand with these ions, many of which are present 
as contaminants in blood products (161) .
The neutral complexes formed between citrate, aluminium 
and other trace metals would be expected to pass through 
cell membranes of the renal glomeruli. When infused in 
albumin metal-citrate should be rapidly excreted in the 
urine. The studies in Chapter four confirm that this 
statement is true for aluminium. Although the
interactions are complex it is possible that ions such as 
ferric, chromium and aluminium with higher binding 
constants to citrate would be excreted more efficiently 
than other ions such as manganese with lower stability 
constants.
The contamination of albumin with citrate, aluminium and
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other trace metals, and its infusion into patients with 
normal renal function provides a unique opportunity to 
study the effect of citrate on the speciation of these 
metals and its role in reducing toxicity by enhancing 
renal elimination.
Several collaborative investigations were undertaken with 
the following objectives.
1 . To assess citrate concentrations in albumin and at 
various stages of the manufacturing process.
2. Gel filtration studies to investigate the speciation 
of metal ions aluminium, chromium, manganese, 
selenium, nickel and the proportion of these ions 
associated with citrate.
3. The effect of ultrafiltration on the concentrations of 
citrate, aluminium, chromium, manganese, iron and 
citrate in albumin.
*1. Comparison of balance studies for aluminium, chromium,
manganese and iron using ultrafiltered albumin with 
similar studies using contaminated albumin.
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6.2. CITRATE AND ALUMINIUM CONCENTRATIONS AT VARIOUS
STAGES OF PRODUCTION CYCLE OF ALBUMIN INCLUDING 
THE NEW ULTRAFILTRATION STEP
6 .2 . i STUDY DESIGN
Samples were taken from two continuous runs of the albumin
(4.3%) production cycle of the Protein Fractionation
Centre, Scottish National Blood Transfusion Centre.
Aluminium
Aluminium concentrations were determined by electrothermal 
atomic absorption spectroscopy.
Citrate
The citric acid content of the samples was determined
using a UV-method (Boehringer-Mannheim GMBH, Biochemica
1986), based on the following:
a) Citrate lyase oxaloacetate + acetate.
+
b) Oxaloacetate + NADH + H Malate dehydrogenase L-Malate 
+ NAD +
+
c) Pyruvate + NADH + H Lactate dehydrogenase L-Lactate 
+ NAD+
The amount of NADH oxidised in reactions b and c is
stoichiometric with the amount of citrate. NADH is 
-determined by means of its absorbance at 340nM.
1 10
Reagents were obtained in a test kit (Citric acid - UV 
method, Biochemica) and determinations carried out using a 
Cobas Mira spectrophotometer.
6 .2.ii RESULTS
Citrate concentrations remain high throughout the 
fractionation process and can therefore chelate aluminium 
and metal ions which are present during the production 
cycle (Figure 6.1).
This study confirms the results of Chapter five which 
showed that most of the contaminating aluminium was added 
during the depth filtration stage and following the 
ultrafiltration step there are low concentrations of 
contaminant aluminium and citrate in albumin solutions.
Acknowledgement: The data in this section was
kindly made available by Mr
William McBey, Protein
Fractionation Centre Scottish
National Blood Transfusion
Service.
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Figure 6.1
CITRATE AND ALUMINIUM LEVELS THROUGHOUT THE FRACTIONATION 
PROCESS (CSVM)
Plasma Al: 0.1 urool/L
(feedstock) Citrate: 18 mmol/L
i-
Supernatant I + II + III Precipitate I + II + ill
Al: 0.1 umol/L Al: 0.1 umol/L
Citrate 12.2 mmol/L Citrate 1.8 mnol/L
Depth Filtration
Supernatant I V  <r
Al: 17-3 umol/L
Citrate: 13.2 mmol/L
Precipitate IV
Al: 0.1 umol/1
Citrate 3-6 mmol/L
Supernatant IV^  + V
Al: 13-6 umol/L
Citrate 9-6 mmol/L
Precipitate IV^ + V
Al: 5-4 umol/L
Citrate: 6.2 mmol/L
Albumin 4.3% — > Ultrafiltration — > *New cleaned up* Albumin 4.3% 
Al: 25 umol/L Al: 1.0 umol/L
Citrate: 5-9 mmol/L Citrate: 0.1 mmol/L
6.3. THE EFFECT OF ULTRAFILTRATION ON THE
CONCENTRATIONS OF ALUMINIUM, CHROMIUM, MANGANESE,
IRON AND CITRATE IN ALBUMIN SOLUTIONS
6.3.i STUDY DESIGN
Aluminium, chromium, manganese and iron concentrations 
were determined by inductively coupled mass plasma 
spectrometry. Citrate concentrations were determined as 
previously described.
Batches of albumin (4.3%) produced by the Edinburgh 
Protein Fractionation Centre, Scottish National Blood 
Transfusion Service were selected at random from supplies 
of albumin available for clinical use in June 1989 in the 
Blood Products Laboratory of the Royal Infirmary, Glasgow. 
In addition, samples of albumin (4.3%) (ultrafiltered) 
were supplied by the Edinburgh Protein Fractionation 
Centre Scottish National Blood Transfusion Centre. For 
comparison a batch of albumin (331050720) manufactured 
before the introduction of the new ultrafiltration process 
was also tested.
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6.3.ii RESULTS
In the ’new’ albumin solutions, citrate concentrations are 
now normal (Table 6.1). Aluminium has also been reduced 
to plasma reference concentrations of around 1 umol/1 or 
less and the problem of aluminium toxicity secondary to 
albumin should now be eliminated.
There have been marked reductions in chromium, manganese 
and iron concentrations and their concentrations are 
marginally elevated above the reference plasma range. 
There is some variation between batches and frequent 
monitoring will be required to ensure that the 
concentrations remain low.
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6.4. GEL FILTRATION STUDIES ON ALBUMIN TO
DETERMINE THE SPECIATION OF ALUMINIUM, CHROMIUM, MANGANESE, 
IRON AND CITRATE IN ALBUMIN SOLUTIONS
6 . 4 . i STUDY DESIGN
A disposable "PD10" column (Sephadex G25) was loaded with 
2.5ml of 5% albumin. A Volume of 3*5ml of phosphate 
buffer was then added and the effluent collected for 
analysis. The material passing through the column is 
considered to be the protein-bound fraction. The fraction 
remaining on the column has entered the gel and is of low 
molecular weight (10,000 Dalton or less).
Aluminium, chromium, manganese, iron and nickel 
concentrations were determined using inductively coupled 
plasma mass spectrometry. Citrate concentrations were 
determined as previously described. The percentage of 
the initial metal and citrate present in albumin as a low 
molecular complex is calculated.
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6 . 4 . ii RESULTS
No data is available for chromium due to analytical 
problems.
The albumin solutions contained 5.7mmol/l citrate (Table 
6.2)which is simil-ar to the citrate level obtained by the 
Protein Fractionation Centre, Scottish National Blood 
Transfusion Service for a different batch of 4.3% albumin 
(Figure 6.1).
Most of the aluminium and chromium present in albumin is 
bound to citrate in a low molecular weight fraction 
(10,000 Daltons) and is therefore ultrafilterable. This 
is confirmed by the close correspondence of these results 
to the ultrafilterable fractions reported by the Protein 
Fractionation Centre Scottish National Blood Transfusion 
Service.
Nickel is highly protein-bound and therefore has a low 
ultrafilterable fraction. Significant amounts of this 
metal will remain as a contaminant in albumin solutions.
The calculations show that about 50% of iron should be 
present as citrate complexes. However these results have 
to take into account the competitive binding of iron with 
transferrin which is present in varying amounts in 
different batches of albumin.
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6.5. COMPARISON OF BALANCE STUDIES FOR ALUMINIUM
CHROMIUM, MANGANESE AND IRON USING ULTRAFILTERED 
ALBUMIN WITH SIMILAR STUDIES USING CONTAMINATED
ALBUMIN
6.5 . i GENERAL CONSIDERATIONS
Since most of the aluminium and other metals (except 
nickel) and citrate have been removed by ultrafiltration 
from albumin solutions, it can be assumed that there 
should be very little urinary excretion of metals in 
patients with good renal function.
6 .5.ii STUDY DESIGN
To test this hypothesis, balance studies for aluminium, 
chromium, manganese and iron were carried out on a patient 
(creatinine clearance 52 ml/m) receiving plasma exchange 
with the ’new’ ultrafiltered albumin solution (Table 6.3). 
The protocol for plasma exchange, and balance studies were 
the same as for patients studied in chapter four. One of 
the previously studied patients (IM) and with a similar 
level of renal function (creatinine clearance 55mls/min) 
was used as a control (Table 4 . 1 ) .  This patient had 
received the 'old’ citrate and metal contaminated albumin 
and the urinary excretion of aluminium, chromium, 
manganese and iron were measured.
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6.5.iii RESULTS
The load of aluminium infused in the ’new’ ultrafiltered 
albumin solution is now negligible and is in fact less 
than the daily basal excretion of aluminium absorbed from 
natural sources (Table 6.4). There is no change in plasma 
concentrations or urinary excretion post-plasma exchange 
and most of the aluminium infused is removed in the 
exchange plasma (Table 6.5). The results show that the 
concentrations of aluminium in the ultrafiltered albumin 
solutions no longer pose a threat of toxicity in patients 
with impaired renal function.
The small amounts of chromium, manganese and iron infused 
in the ’new’ ultrafiltered albumin do not cause any
observed change in plasma concentrations (Table 6.5). The 
exchange fluid is now the main route of elimination of 
those metals during plasma exchange since there is no net 
urinary excretion of these metals (Table 6.4).
These results contrast sharply with the high
concentrations of aluminium, chromium, manganese and iron 
observed in the patient with a similar level of renal 
function and who was plasma exchanged with the
contaminated albumin (Figure 6.2, Figure 6.3).
These results confirm the original hypothesis and suggests 
that citrate has an important role in the renal
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elimination of these metal ions as a result of the 
formation of low molecular weight citrate-metal complexes.
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6.6. DISCUSSION
The gel filtration data and the metabolic balance studies 
provide experimental and clinical evidence for the
important role of citrate in the speciation of metal ions 
in albumin solutions. It is therefore very likely that
Citrate prevents metal retention and toxicity in those 
patients with normal renal function by promoting a most 
efficient renal excretion of aluminium and other metals 
with which it forms neutral low molecular weight 
complexes.
Further evidence for this important role of citrate is 
seen when the incidence of bone disease in patients with 
normal renal function receiving aluminium contaminated 
total parenteral nutrition (casein hydrolysate) is 
compared with similar patients receiving aluminium 
contaminated albumin.
The total parenteral nutrition caused aluminium bone 
disease in patients with normal renal function (88) while 
patients with good renal function who were injected with 
large amounts of aluminium in albumin during long term 
plasma exchange showed no evidence of bone disease 
(Chapter four) (96) (99). The percentage urinary excretion 
of an aluminium load in patients receiving total 
parenteral nutrition varied from 5 to 20% compared to 
almost 100% in patients receiving albumin (Chapter four).
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An important difference between the two intravenous 
sources of aluminium contamination is that the total 
parenteral nutrition contained no citrate whereas albumin 
solutions contain ten to fifteen times the normal plasma 
citrate concentrations.
The ’new’ ultrafiltered albumin solutions show normal 
concentrations of aluminium and marginally elevated values 
for chromium, manganese and iron with negligible 
retention. These ultrafiltered albumin solutions should 
be safe for injection in patients with impaired renal 
function.
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CHAPTER 7
FINAL DISCUSSION AND CONCLUSION
CONCLUSION
These results provide evidence for a previously 
unrecognised toxic effect of treatment with albumin 
solutions.
The albumin solutions analysed contained up to forty times
the aluminium normally present in fresh frozen plasma, the
starting material for its manufacture. Other blood
products including coagulation factors such as factor 
VIII, Prothrombin Complex, as well as immunoglobulin 
preparations had similar concentrations of aluminium 
contamination. There was also a widely varying trace 
metal contamination of albumin and blood products which 
occurred during the manufacturing process.
A recent report,(99) shows that the concentrations of 
aluminium in albumin solutions from most manufacturers 
remain unacceptably high.
As a direct result of the information on aluminium 
toxicity in this thesis, two manufacturers Merieux (157) 
and the Protein Fractionation Centre, Scottish National 
Blood Transfusion Service, Edinburgh,(154) have introduced 
stages in the manufacturing process to remove the 
aluminium and trace metals which contaminate their albumin 
products.
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The Protein Fractionation Centre,Scottish National Blood 
Transfusion Service have carried out detailed and 
extensive investigations of their manufacturing process. 
They have identified the sources of contamination which 
include depth filters, sodium hydroxide solutions used for 
pH adjustment, stainless steel processing equipment and 
stabilisers such as caprylic acid. They have successfully 
introduced an ultrafiltration step and recent analysis 
shows that their albumin solutions are the ’cleanest’ now 
available commercially. The results of their
investigations will be of value to manufacturers who use a 
similar process and should encourage other manufacturers 
to follow their example.
It is understandable that until recently manufacturers 
have been reluctant to accept that albumin solutions are a 
potential cause of metal toxicity. There is now
considerable evidence in the literature for aluminium as a 
toxic agent. However, the biological activity and
clinical importance of marginal depletions or accumulation 
of other trace elements remains uncertain. At present
unequivocal evidence is not available to show that these 
contaminating metals pose health risks.
The toxicity of aluminium is clearly recognised and this 
cannot be ignored by the manufacturers of contaminated 
albumin and clinicians who treat their patients with these 
products.
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In patients with chronic renal failure, aluminium has been 
implicated in the pathogenesis of Vitamin D resistant 
osteomalacia, dialysis encephalopathy and microcytic 
anaemia.(1)
The administration of albumin to patients with renal 
insufficiency is of - particular importance since the kidney 
is the main route for aluminium elimination and 60 to 70% 
of an aluminium load may be retained, resulting in bone 
disease.
The pattern of aluminium bone disease is dependent on 
parathyroid gland activity as well as variations in the 
duration and frequency of aluminium loads administered in 
albumin solutions. Extensive aluminium bone deposition is 
seen in euparathyroid patients receiving weekly plasma 
exchanges with albumin.
Intravenous desferrioxamine infusions increase the urinary 
output of aluminium and may be a useful therapeutic 
procedure in patients with evidence of aluminium 
retention.
In individuals with normal renal function, who receive
aluminium contaminated albumin, the kidneys excrete most
of the aluminium load and significant bone pathology is
not seen. In contrast, aluminium bone disease occurs in 
patients with normal renal function, who receive total
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parenteral nutrition containing casein hydrolysate with 
similar concentrations of aluminium as albumin (87). The 
serum binding and urinary excretion patterns of aluminium 
and trace metals are different in these two groups of 
patients. In the total parenteral nutrition group,
aluminium binds strongly to plasma proteins with a low 
excretion of aluminium and resultant bone disease. 
Whereas in the albumin group almost all of the 
contaminating metals are excreted in the urine.
Citrate concentrations in albumin are ten to fifteen times 
greater than in normal plasma. It is an efficient 
chelator of aluminium and other metal ions in plasma and 
it is likely that the citrate contamination of albumin is 
protecting patients with normal renal function by 
enhancing metal excretion and reducing toxicity.
In patients with renal impairment, aluminium citrate 
accumulates and this is a potent bone poison which 
accelerates the development of osteomalacia (120).
Although an aluminium induced osteomalacia is a well 
established effect of chronic aluminium toxicity, 
neurotoxicity is also recognised and there is interest in 
the role of aluminium in the development of Alzheimer’s 
disease and other degenerative conditions related to 
ageing.
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In Martyn’s report (3) the risk of Alzheimer’s disease was 
one and a half times higher in districts where the mean 
concentration of aluminium in water exceeded 4 umol/1. 
The absorption of aluminium from the gastrointestinal 
tract is very small and less than 1% of the aluminium 
present in water would be expected to enter the blood 
stream. The concentrations in water are very low
compared to the 40 umol/1 of parenteral aluminium infused 
with each litre of albumin solution.
There is considerable debate over the role of aluminium as 
the primary cause of Alzheimer’s disease, but nevertheless 
if the association between Alzheimer’s disease and 
aluminium is true then patients who retain aluminium while 
receiving treatment with albumin could be at risk of 
developing this disease.
iK
The current European Economic Commission Directive limits 
the aluminium concentration of drinking water to 7.4 
umol/1 (200ug/l). In view of the recently recognised risk 
of aluminium toxicity from albumin solutions a tentative 
reference value of 7.4 umol/1 was agreed at a recent 
European Pharmacopoeia Commission meeting.
There is a great contrast in the attitudes of authorities 
like the European Pharmacopoeia Commission to metal 
toxicity in relation to aluminium and other trace metals 
when compared with the present ideas in relation to lead,
mercury and arsenic. If these heavy metals were present 
as contaminants in albumin solutions then manufacturers 
would have been under greater pressure to eliminate this 
contamination. The major emphasis in safety in the 
production of blood products is rightfully on 
microbiological and viral contamination. However, modern 
analytical techniques such as atomic absorption 
spectroscopy and inductively coupled plasma mass 
spectrometry can show up low concentrations of metal 
contamination which have not been formerly recognised.
It is probably fortuitous that the increase in aluminium 
in albumin is accompanied by an increase in citrate, 
otherwise this product would have been manifestly and 
immediately toxic in patients with normal renal function.
On the basis of the present evidence if manufacturers are 
to produce an ideal albumin solution for clinical use then 
apart from maintaining bacteriological and viral sterility 
they must aim at restoring the metal content of these 
solutions to concentrations as close as possible to normal 
plasma. They should aim to remove low molecular weight 
contaminants such as alcohol, citrate and citrate complex 
metals as well as highly protein bound metal contaminants 
such as nickel.
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APPENDIX I .
ALUMINIUM ( A 1) METABOLIC BALANCE STUDY
Example of calculation
Patient:
Date of Plasma Exchange
Total Volume of Plasma Exchanged
Batch No. of Albumin 4.3%
Aluminium Level (331050720)
Total Aluminium Infused
ALUMINIUM OUTPUT 
Exchange Fluid
Date Volume /Litres A1 Level
(umol/1)
13.4 Bag 1: 1.6 1 .8
2 : 0.8 1.7
Aluminium Output = 4.3 umol.
13th April
2.8 Litres 
331050720
19.7 umol/1
55.2 umol
Total A1 Level 
(umol)
2.9 
1 .4
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URINE
Before Plasma Exchange
Basal Urinary Aluminium Level 
24 hr Urine Volume x Urine A1 Level (umol/1)
1 .85 x 0.4 
= 0.7 umol
After Plasma Exchange
Date
13-14/4
14-15/4
15-16/4
Volume (L)
1 .60 
1 .95 
2.0
A1/Cone 
(umol/1) 
13.5
2.4
2.0
A1 Output 
(umol)
21 .6
4.7
4.0
Aluminium Output = 30.3 umol
Urinary Aluminium (Aluminium output - 3 day Basal Urine
Aluminium Cone.)
= 28.1 umol
Total Aluminium Output (Urine and Exchange Fluid)
= 32.3 umol
% Aluminium Recovery =
.Total A1 Output -f A1 infused in Albumin x 100
= 58%
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APPENDIX I I
DESFERRIOXAMINE (DFO) MOBILIZATION TEST 
Example of Calculations 
Patient: M .C.
Plasma
Plasma Aluminium Concentrations (umol/1)
Pre DFO - 0.6
Post DFO 
24 hrs - 3.2
48 hrs - 3*0
72 hrs - 1.8
Increase in Plasma Aluminium Level (umol/1) 
= Post DFO - Pre DFO
24 hrs - 2.6
48 hrs - 2.4
72 hrs - 1.2
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URINE
Urine Volume(L) Urinary A1 Urinary A1 Content (umol) 
(24 hours) (umol/1) (Urine Vol x Urinary Al)
Pre DFO
1.2 1.1 1 . 3(basal Al)
Post DFO 
1st 24 hr
1.1 L 19.2 21.1
2nd 24 hr
1.4 L 14.6 20.4
3rd 24 hr
1 .4 L 8.7 12.2
Net Urinary Aluminium Level (umol) =
Urinary Al - Basal Al Excretion
24 Hour Period Post DFO 
1st 19.8 
2nd 19.1 
3rd 10.9
Total Urinary Aluminium Excretion Post DFO Infusion 
= 49.8 umol/1
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APPENDIX I I I
PLASMA PROTEIN FRACTIONATION AND PREPARATION OF BLOOD
PRODUCTS
Introduction
Almost 40 years after the pioneering work of E.J. Cohn and 
his associates, most of the plasma processing throughout 
the world is still fractionated following the basic 
alcohol method (162). There have been modifications,(163) 
but the aim of most of these changes has been the 
economical production and good yield of the few proteins 
that are used in large quantities in clinical practice. 
The fractions produced for clinical use are albumin (5% or 
20%), immunoglobulins, Factor VIII concentrates, 
concentrates containing Factor IX in association with 
other coagulation factors and antithrombin III 
concentrates.
Ethanol: Cohn Fractionation
Ethanol has been used now for several decades in plasma 
fractionation and it causes precipitation of proteins 
mainly because it significantly lowers the dielectric
constant of the aqueous solution. The following
properties of ethanol make it ideal for organic solvent
precipitation:
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1. Miscibility with water.
2. Melting point depression to - 22°C. at a concentration 
of 32% (w/w).
3. No generation of explosive gas mixtures under normal 
ambient and working conditions.
4. Low molecular weight of only 46 daltons.
5. Highly volatile
6. Chemically relatively inert
7. Low toxicity
8. Inexpensive and easily available
The advantage of ethanol which is of paramount importance 
in a fractionation process is its inhibition of bacterial 
growth and thus of pyrogen formation. This inhibition 
also results indirectly from the low temperatures needed 
when working with ethanolic protein solutions.
The preparation of pure proteins (Table A III.1) from 
plasma is facilitated by the influence of several factors 
on the precipitation action of alcohol. These factors are 
pH, ionic strength, temperature and protein concentration, 
i.e. the ”five parameter system”. Separations are carried 
out in two different ways:
Conditions are chosen to maximise solubility of the 
desired protein and minimise solubility of all others. 
The desired protein stays in solution while all others 
precipitate, or the converse conditions are chosen where
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the desired protein will then be selectively precipitated.
Plasma fractionation is carried out in large tanks or
jacketed vessels with agitation. Adjustment to pH, ionic
strength and protein concentration is made in these
vessels either by direct titration or by calculation
following titration of samples from the bulk pool'. When 
precipitation is complete and the mixture has been allowed 
to equilibrate fully, it is then passed to a filter or a 
temperature controlled centrifuge for phase separation. 
The process is a semi - continuous flowing stream which is 
conditioned sequentially and separated without stopping.
At donor centres whole blood is collected in donation 
packs which contain Citrate - Dextrose - Phosphate Adenine 
as the anticoagulant. Plasma is separated from the cells 
into single donation plasma packs, frozen and transported 
to the fractionation centre where it is stored frozen at - 
40°C until required.
Liquid-solid separations are critical in all plasma 
fractionation procedures in order to harvest desired 
products and remove contaminants such as lipids, denatured 
proteins and micro-organisms. Filtration and
centrifugation are the two methods generally used. 
Filtration is used after centrifugation steps as a 
polishing operation for the removal of small amounts of 
solids in order to achieve clarification, purification,
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stabilization and final sterilization.(160) Depth filters 
are most often used as prefilters upstream of surface 
filters that usually provide final clarification and 
sterilization.
The objective of prefiltration is to increase the
filterability of the fractions, to and though the final 
filter, so that a satisfactory through-put and rate can be 
achieved.
A surface or screen filter is a geometrically regular 
porous matrix that traps particles at its surface by a 
sieving mechanism. The surface filter is not designed for
high dirt-loading capacity and its rapid plugging is
typical. For this reason, surface filters normally used 
for sterilization, stabilization or clarification are
usually preceded by depth filters.
A depth filter has a random and tortuous porosity and is 
capable of retaining particles throughout its matrix 
rather than solely on the surface.
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Preparation of Albumin and Other Blood Products
Prior to fractionation the frozen plasma is pooled by 
passing the frozen blocks through an enclosed ice-crushing 
plant and then to a large pooling vessel. 
Cryoprecipitation is the first step (Figure A III.1) and 
results from the formation of regions of high 
concentrations of solutes such as proteins and salts in 
the inter-crystalline spaces of the ice lattice during 
freezing. Frozen plasma is allowed to thaw slowly to 4 C 
and the cryoprecipitate collected in continuous flow 
centrifuges. Intermediate factor VIII concentrates are 
then produced by extraction of the cryoprecipitate with 
buffer, and this is followed by an absorption with 
aluminium hydroxide to remove prothrombin and other 
contaminants. The intermediate purity factor VIII so 
produced undergoes sterile filtration for clarification of 
the product and lyophilization for solvent removal and 
freeze drying prior to heat treatment to inactivate 
viruses including HIV.
Ethanol fractionation of the supernatant following 
cryoprecipitate removal results in five fractions, I, II 
and III, IV-4 and V, as shown in figures (Figure A III.2).
Fraction I was used for preparing fibrinogen, which is no 
longer a licensed product due to its high risk of 
hepatitis and limited clinical limitations.
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Plasma
freeze/thaw
Cryoprecipitate 
Depleted Plasma
saved for further
fractionation
Cryoprecipitate
extraction with 0.02M 
Tris-HCI, pH 7.0 
Temperature 0-2°C
Supernatant
discarded
Cold Extracted 
Cryoprecipitate
extracted with 0.02M 
Tris-HCI, pH 7-0 
Temperature 20-25°C Al 
(0H)3 absorption
Supernatant Precipitate
Temperature 10 C discarded
i-----------
Fibronectin 
Depleted Factor VIII
Ultraf iltration 
Sterile filtration 
Lyophilization
Crude Fibronectin Precipitate
saved for further 
purification
Factor VIII Concentrate
Figure A III.I: Preparation of Factor VIII Concentrate.
Plasma
Ethyl alcohol 8% 
Temperature -3°C
Protein 5.1%
Supernatant I
Ethyl alcohol 25% pH 6.9
Temperature -5 C P/2 0.09
Protein 3-0%
Supernatant II + III
Ethyl alcohol 18% pH 5-2 
Temperature -5 C P/2 0.09 
Protein 1.6%
pH 7.2 
P/2 0.14
Precipitate I 
discarded
Precipitate II + III
saved for the 
preparation of IgG*
Ethyl alcohol 40Jk 
Temperature -5 C
Supernatant IV-I
pH 5.8
Protein 1.0%
P/2 0.09
Precipitate IV-I
saved for the prep, 
of prothrombin complex 
or discarded
Supernatant IV-4
Ethyl alcohol 40% pH 4.8
Temperature -5 C P/2 0.11
Protein 0.8%
I
Precipitate IV-4 
discarded
Supernatant V 
discarded
Precipitate V
Ethyl alcohol lOg 
Temperature -3 C
Protein 3.0%
Supernatant
Ethyl alcohol 40^ 
Temperature -5 C
Protein 2.5%
pH 5.2
p/2 0.01
pH
P/2
Impurities
discarded
4.5
0.1
Superbatant
Albumin
Figure A III.2: Flowsheet for the preparation of albumin.
Ihe parameters of ethyl alcohol concentration, temperature,protein 
concentration, Ph and ionic strength (P/2) are given for each 
fractionation.
IgG - IgG immunoglobulin
hepatitis and limited clinical limitations.
Fractions II and III are sub-fractionated to prepare 
immunoglobulin. In addition proteins such as
lipoproteins, plasminogen, prothrombin and isoglutinins 
may also be recovered, but only immunoglobulin is 
currently prepared as a licensed clinical product.
Fraction IV-4 is discarded and Fraction V is used to 
prepare albumin solutions for clinical use.
Before the final product is prepared for clinical use, the 
various concentrates obtained from Cohn fractionation must 
be treated to remove any alcohol which remains in the 
terminal fraction as an unwanted contaminant at a 
concentration which may affect the solubility and 
stability of the product. In addition to ethanol, water 
may be present as a dilutent in excess of what is required 
in the final solution and so treatment is also required to 
remove this water and raise the protein concentration to 
specified concentrations. The process of thin film
evaporation is used to remove unwanted alcohol and water 
from the protein concentrations. The solution to be 
treated is spread under vacuum and flows over a supporting 
surface to which heat is applied. The conditions promote 
a high rate of evaporation in a system which is designed 
to maintain rapid transfer of heat without imposing 
excessive temperature gradients while operating
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continuously.
Finally, the concentrates are filtered to produce products 
which are free of contaminants such as lipids, denatured 
proteins and micro-organisms.
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APPENDIX I V .
BALANCE STUDIES FOR ALUMINIUM, CHROMIUM, MANGANESE AND 
IRON USING ’NEW CLEANED UP’ SOLUTION
Patient: C.R.
Date of Plasma Exchange 15th June 1989
Diagnosis: Guillain-Barre
Total Volume of Plasma Exchange: 2.8 litres
Batch No. of albumin 4.3% 331182710
METAL INPUT
Metal concentration: 
Total amount infused
Aluminium
0 .7(umol/1)
1 . 96(umol/I)
Chromium 
504(nmol/I) 
1411.2(nmol/I)
Metal concentration: 
Total amount infused
Manganese 
174(nmol/I)
Iron 
41(umol/1)
487.22(nmol/l) 114.8(umol/1)
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METAL OUTPUT IN  EXCHANGE FLUID
Volume of Exchange Fluid = 2.4 1
Aluminium Chromium
Metal concentration: 0.5(umol/l) 575(nmol/l)
Metal output in 
exchange fluid: 1.23(umol/l) 1414.5(nmol/l)
Manganese Iron
Metal concentration 29•7(nmol/I) 12(umol/l)
Metal output in 
exchange fluid: 73(nmol/l) 29-5(umol/l)
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METAL OUTPUT IN  URINE
P re  P lasm a  E xch ange
Urine Volume = 1.5 1 
Aluminium
Urinary metal
concentration: i.96(umol/l)
Total urinary
metal excretion: 2.94(umol)
Manganese
Urinary metal
concentration: 7(nmol/l)
Total urinary
metal excretion: 10.5(nmol)
Post Plasma Exchange
Day 1 .
Urine Volume = 1.32 1 
Aluminium
Metal concentration: 1.80(umol/l)
Total concentration: 2.34(umol)
*Net metal excreted : 0
Chromium 
6.4(nmol/I)
9.6(nmol) 
Iron 
0.2(umol/I)
0.3(umol)
Chromium 
4.8(nmol/I) 
6.2(nmol)
6.2(nmol)
* NB: Net metal excreted = Metal cone. Post exchange -
Metal conc. Pre exchange.
Metal concentration: 
Total concentration: 
Net metal excreted:
Manganese 
7 (nmol/1) 
9 .1 (nmol) 
0
Iron 
0.2 (umol/1) 
0.3 (umol)
0
Day 2
Urine Volume = 1.2 1
Metal concentration: 
Total concentration: 
Net metal excreted:
Aluminium 
1.6 (umol/1) 
1.92 (umol)
0
Chromium
1.9 (nmol/1)
2.3 (nmol)
1.3 (nmol)
Manganese
Metal concentration: 7 (nmol/1)
Total concentration: 8.4 (nmol)
Net metal excreted: 0
Total Urinary Metal Excreted (day 1 and 2)
Aluminium Chromium Manganese Iron
0 7.5 (nmol) 0 0
Iron
0.2 (umol/1) 
0.2 (umol)
0
1 4 1b
CITRATE BALANCE STUDIES
INPUT
Albumin
Citrate level: 0.1 mmol/1
Citrate load infused = 2.8 x 0.1 = 0.28 mmol
OUTPUT
A. Plasma Bag: 
Citrate:
Citrate removed:
B. Urine Output:
0.1 mmol/I 
0.25 mmol
Urine Output Pre-Exchange
Citrate concentration 
Basal Output
1.29mmol/I 
1.94 mmol
Urine Output Post Exchange
Day 1 Citrate concentration 
Citrate Output
1.20 mmol /I 
1.44 mmol
Day 2 Citrate concentration 
Citrate Output
1.35 mmol /I 
1.69 mmol
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